var title_f24_29_25040="Parenchymal asymmetry";
var content_f24_29_25040=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Parenchymal asymmetry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 240px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A focal asymmetry (arrow) is seen in the lateral aspect of the breast on the CC view. A follow up mammogram is usually obtained to assess stability.",
"    <div class=\"footnotes\">",
"     CC: craniocaudal.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25040=[""].join("\n");
var outline_f24_29_25040=null;
var title_f24_29_25041="Linear morphea";
var content_f24_29_25041=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51218&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Linear morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A shiny, sclerotic, hyperpigmented plaque is present in a linear distribution on the arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25041=[""].join("\n");
var outline_f24_29_25041=null;
var title_f24_29_25042="Infantile myofibroma back";
var content_f24_29_25042=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61534&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infantile myofibromatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, firm nodules are present on the trunk and arm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25042=[""].join("\n");
var outline_f24_29_25042=null;
var title_f24_29_25043="Gram stain sputum 12C answer";
var content_f24_29_25043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75864&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspergillus fumigatus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Silver-stain of lung tissue (x400) shows septate hyphae with acute angle branching characteristic of Aspergillus fumigatus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25043=[""].join("\n");
var outline_f24_29_25043=null;
var title_f24_29_25044="Nodular acne - face";
var content_f24_29_25044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular acne",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules, pustules, and nodules are present on the face. This patient also has postinflammatory hyperpigmentation and scarring.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25044=[""].join("\n");
var outline_f24_29_25044=null;
var title_f24_29_25045="Calcium glubionate: Pediatric drug information";
var content_f24_29_25045=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Calcium glubionate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?36/46/37604?source=see_link\">",
"    see \"Calcium glubionate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?13/24/13700?source=see_link\">",
"    see \"Calcium glubionate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3274451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calcionate [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1002983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Salt",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Electrolyte Supplement, Oral",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     200 mg/day of",
"     <b>",
"      elemental calcium",
"     </b>",
"     ; requirements may vary on prematurity, postnatal age, and other clinical factors; serum calcium concentrations should be monitored closely to determine patient-specific needs",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     Dose depends on clinical condition and serum calcium concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose expressed in mg of",
"     <b>",
"      elemental calcium",
"     </b>",
"     : 50-150 mg/kg/day in 4-6 divided doses; not to exceed 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose expressed in mg of",
"     <b>",
"      calcium glubionate",
"     </b>",
"     : 1200 mg/kg/day in 4-6 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1003008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/46/37604?source=see_link\">",
"      see \"Calcium glubionate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental calcium:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-6 months: 200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 260 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Dosage expressed in terms of",
"     <b>",
"      elemental calcium;",
"     </b>",
"     during pregnancy and lactation, requirements may change:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 700 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-18 years: 1300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females 19-50 years, males 19-70 years: 1000 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females &ge;51 years, males &ge;71 years: 1200 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dietary supplement:",
"     </b>",
"     Dosage below based on product containing: 1.8 g calcium glubionate/5 mL (115 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     /5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants &lt;12 months: 5 mL/dose 5 times a day; may mix with juice or formula",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &lt;4 years: 10 mL/dose 3 times a day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;4 years and Adolescents: 15 mL/dose 3 times a day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 15 mL/dose 3 times a day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Pregnant or lactating women: 15 mL/dose 4 times a day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypocalcemia:",
"     </b>",
"     Dose depends on clinical condition and serum calcium concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose expressed as",
"     <b>",
"      elemental calcium",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children: 45-65 mg/kg/day in 4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 1-2 g or more per day in 3-4 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dose expressed as",
"     <b>",
"      calcium glubionate",
"     </b>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants and Children: 600-2000 mg/kg/day in 4 divided doses up to a maximum of 9 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adults: 6-18 g/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Adjunctive prevention and treatment of osteoporosis:",
"     </b>",
"     Adults: 500 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     2-3 times/day; recommended dosage includes dietary intake and should be adjusted depending upon the patient&rsquo;s diet; to improve absorption do not administer more than 500 mg",
"     <b>",
"      elemental calcium",
"     </b>",
"     /dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;25 mL/minute may require dosage adjustment depending upon serum calcium level",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F144577\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calcionate: 1.8 g/5 mL (473 mL) [contains benzoic acid; caramel-orange flavor; equivalent to elemental calcium 115 mg/5 mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F144563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3429796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer with plenty of fluids with or following meals; for phosphate binding, administer on an empty stomach before meals to optimize effectiveness",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F3429795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1002984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment and replacement of calcium deficiency; dietary supplement; adjunctive prevention and treatment of osteoporosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F144627\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Calcium glubionate may be confused with calcium gluconate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F144625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Symptoms reported with hypercalcemia:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, nausea, thirst, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Polyuria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1002986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to calcium formulation; hypercalcemia, renal calculi, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F3429089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use cautiously in patients with sarcoidosis, respiratory failure, acidosis, renal or cardiac disease; some products may contain aspartame which is metabolized to phenylalanine and must be avoided in patients with phenylketonuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1002987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Multiple salt forms of calcium exist; close attention must be paid to the salt form when ordering and administering calcium; incorrect selection or substitution of one salt for another without proper dosage adjustment may result in serious over- or under-dosing. Some products may contain tartrazine which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F144571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Calcium Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Acetate: Calcium Salts may enhance the adverse/toxic effect of Calcium Acetate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Calcium Salts may diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Calcium Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOBUTamine: Calcium Salts may diminish the therapeutic effect of DOBUTamine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Calcium Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any polyvalent cation (e.g., calcium-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estramustine: Calcium Salts may decrease the absorption of Estramustine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May increase the serum concentration of Calcium Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Calcium Salts may decrease the absorption of Phosphate Supplements.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Calcium Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Moxifloxacin (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: Calcium Salts may decrease the serum concentration of Strontium Ranelate.  Management: Separate administration of strontium ranelate and oral calcium salts by at least 2 hours in order to minimize this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Calcium Salts may decrease the serum concentration of Tetracycline Derivatives.  Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: Calcium Salts may diminish the therapeutic effect of Thyroid Products.  Management: Separate the doses of the thyroid product and the oral calcium supplement by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Calcium Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Calcium Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Calcium Salts may enhance the adverse/toxic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1003000\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not give orally with bran, foods high in oxalates (spinach, sweet potatoes, rhubarb, beans), or phytic acid ( unleavened bread, raw beans, seeds, nuts, grains, soy isolates) which may decrease calcium absorption; minimize administration with dairy products (when treating deficiency state) as this will reduce absorption",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13333820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium crosses the placenta. Intestinal absorption of calcium increases during pregnancy. The amount of calcium reaching the fetus is determined by maternal physiological changes. Calcium requirements are the same in pregnant and nonpregnant females (IOM 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F3429090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum calcium (ionized calcium preferred if available), phosphate, magnesium, heart rate, ECG",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1003004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calcium: Newborns: 7-12 mg/dL; 0-2 years: 8.8-11.2 mg/dL; 2 years to adults: 9-11 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Calcium, ionized, whole blood: 4.4-5.4 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1003003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium moderates nerve and muscle performance via action potential excitation threshold regulation; it is necessary for maintaining the functional integrity of nervous, muscular, and skeletal systems and cell-membrane and capillary permeability.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1003005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: 25% to 35%; varies with age (infants 60%, prepubertal children 28%, pubertal children 34%, young adults 25%); decreased absorption occurs in patients with achlorhydria, renal osteodystrophy, steatorrhea, or uremia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Primarily in the feces as unabsorbed calcium",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1003017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     1 g calcium glubionate = 64 mg elemental calcium  = 3.2 mEq calcium. Due to a poor correlation between the serum ionized calcium (free) and total serum calcium, particularly in states of low albumin or acid/base imbalances, direct measurement of ionized calcium is recommended. If ionized calcium is unavailable, in low albumin states, the corrected",
"     <b>",
"      total",
"     </b>",
"     serum calcium may be estimated by this equation (assuming a normal albumin of 4 g/dL); [(4 &ndash; patient's albumin) x 0.8] + patient's measured total calcium",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Elemental Calcium Content of Calcium Salts",
"     </caption>",
"     <col align=\"left\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium Salt",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Elemental Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg/1 g of salt form)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mEq/g)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Approximate Equivalent Doses",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (mg of calcium salt)",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium acetate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         250",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         12.7",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         354",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium carbonate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         400",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         20",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         225",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium chloride",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         270",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         13.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         330",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium citrate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         211",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         10.6",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         425",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium glubionate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         64",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         3.2",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1400",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium gluconate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         90",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         1000",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium lactate",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         130",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         6.5",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         700",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Calcium phosphate (tribasic)",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         390",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         19.3",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         233",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Dietary Reference Intakes for Calcium and Vitamin D",
"      </i>",
"      , Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Ross AC, Taylor CL, et al, eds, Washington, DC: National Academies Press (US), 2011. Available at",
"      <a href=\"file://www.nap.edu/catalog.php?record_id=13050\" target=\"_blank\">",
"       file://www.nap.edu/catalog.php?record_id=13050",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/29/25045/abstract-text/21796828/pubmed\" id=\"21796828\" target=\"_blank\">",
"        21796828",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12897 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25045=[""].join("\n");
var outline_f24_29_25045=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3274451\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002983\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442187\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003008\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144577\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144563\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429796\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429795\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002984\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144627\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144625\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002986\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429089\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1002987\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298940\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F144571\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003000\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13333820\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3429090\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003004\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003003\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003005\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1003017\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12897\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12897|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?36/46/37604?source=related_link\">",
"      Calcium glubionate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?13/24/13700?source=related_link\">",
"      Calcium glubionate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_29_25046="Nicotine: Patient drug information";
var content_f24_29_25046=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nicotine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/4/34887?source=see_link\">",
"     see \"Nicotine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F201268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Commit&reg; [OTC];",
"     </li>",
"     <li>",
"      NicoDerm&reg; CQ&reg; [OTC];",
"     </li>",
"     <li>",
"      Nicorelief&reg; [OTC];",
"     </li>",
"     <li>",
"      Nicorette&reg; [OTC];",
"     </li>",
"     <li>",
"      Nicotrol&reg; Inhaler;",
"     </li>",
"     <li>",
"      Nicotrol&reg; NS;",
"     </li>",
"     <li>",
"      Thrive&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F201269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Habitrol&reg;;",
"     </li>",
"     <li>",
"      Nicoderm&reg;;",
"     </li>",
"     <li>",
"      Nicorette&reg;;",
"     </li>",
"     <li>",
"      Nicorette&reg; Plus;",
"     </li>",
"     <li>",
"      Nicotrol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat nicotine withdrawal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3821502",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to curb the craving to smoke.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702601",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nicotine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703468",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have temporomandibular joint disease and are using the nicotine gum.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are smoking during recovery from a heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       When you stop smoking, other drugs may be affected. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705410",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gum:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696975",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Gum chewing may cause problems with dental work.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705500",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The patch may have metal. Take off the patch before an MRI.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696990",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant and using the patch, think about taking it off at night.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705423",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Puffer (inhaler):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017181\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698131",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hiccups.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698192",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Jaw ache from gum.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698241",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699036",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad mouth pain or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not been able to quit smoking after taking this drug for 12 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3821530",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not smoke when you are using these products. Your body can be harmed by getting too much nicotine too fast.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Get counseling to help you quit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705423",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Puffer (inhaler):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696175",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use puffer (inhaler) as you have been told.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705410",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Gum:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3821522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There are 2 doses of the gum. Use the 4 mg gum if you smoke 25 or more cigarettes a day. Use the 2 mg gum if you smoke 24 or less cigarettes a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not swallow gum.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chew slowly until there is a tingling or peppery taste in the mouth.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695953",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Then place between the cheek and gum.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694396",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After the taste or tingle is gone, chew again slowly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695507",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put between the cheek and gum at some other site once the taste or tingle comes back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695260",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep repeating this for about 30 minutes or until the taste or tingle is gone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694700",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat or drink within 15 minutes of using the gum.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3821526",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use more than 24 pieces of gum a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705500",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Patch:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3821562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The patch comes in 3 doses. If you smoke 11 or more cigarettes a day start with the 21 mg patch (step 1). If you smoke 10 or less cigarettes a day start with the 14 mg patch (step 2).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694481",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put patch on clean, dry, healthy skin on the chest, back, belly, or upper arm. Move the site with each new patch.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3821542",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep each patch on for 16 to 24 hours.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Lozenge:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3821563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The lozenge comes in 2 doses. If you smoke your first cigarette of the day within 30 minutes of waking use the 4 mg dose. If you smoke your first cigarette of the day more than 30 minutes after waking use the 2 mg dose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695691",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Suck oral lozenge. Do not chew, break, or crush it. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not eat or drink within 15 minutes of using the lozenge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nose:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694916",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the nose only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694567",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blow your nose before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695621",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696127",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694631",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Close 1 nostril.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695230",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put nose spray tube into other nostril.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3682982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Spray up the nose only. Do not spray onto the wall joining your two nostrils.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694569",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Breathe out from your mouth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017179\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10907 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25046=[""].join("\n");
var outline_f24_29_25046=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201268\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F201269\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017176\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017175\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017180\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017181\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017183\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017178\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017179\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017184\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017185\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/4/34887?source=related_link\">",
"      Nicotine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_29_25047="Fluticasone (oral inhalation): Pediatric drug information";
var content_f24_29_25047=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluticasone (oral inhalation): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26120?source=see_link\">",
"    see \"Fluticasone (oral inhalation): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/33/12822?source=see_link\">",
"    see \"Fluticasone (oral inhalation): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9349568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flovent&reg; Diskus&reg;;",
"     </li>",
"     <li>",
"      Flovent&reg; HFA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9349569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Flovent&reg; Diskus&reg;;",
"     </li>",
"     <li>",
"      Flovent&reg; HFA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F990183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Inhalant (Oral)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12674645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhalation: Bronchopulmonary dysplasia, treatment: See",
"     <b>",
"      Dosing: Usual",
"     </b>",
"     for dosing  in infants (PNA in clinical trials &gt;28 days)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F990189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26120?source=see_link\">",
"      see \"Fluticasone (oral inhalation): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Oral inhalation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Asthma:  If adequate response is not seen after 2 weeks of initial dosage, increase dosage; doses should be titrated to the lowest effective dose once asthma is controlled:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Inhalation aerosol (Flovent&reg; HFA): Manufacturer's recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children 4-11 years: Initial: 88 mcg twice daily; maximum dose: 88 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Patients previously treated with bronchodilators only: Initial: 88 mcg twice daily; maximum dose: 440 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Patients treated with an inhaled corticosteroid: Initial: 88-220 mcg twice daily; maximum dose: 440 mcg twice daily; may start doses above 88 mcg twice daily in poorly controlled patients or in those who previously required higher doses of inhaled corticosteroids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     Patients previously treated with oral corticosteroids: 440 mcg twice daily; maximum dose: 880 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     NIH Asthma Guidelines (NAEPP, 2007) (give in divided doses twice daily):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &lt;12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     \"Low\" dose: 88-176 mcg/day (44 mcg/puff: 2-4 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     \"Medium\" dose: &gt;176-352 mcg/day (44 mcg/puff: 4-8 puffs/day or 110 mcg/puff: 2-3 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     \"High\" dose: &gt;352 mcg/day (110 mcg/puff: &gt;3 puffs/day or 220 mcg/puff: &gt;1 puff/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     \"Low\" dose: 88-264 mcg/day (44 mcg/puff: 2-6 puffs/day or 110 mcg/puff: 2 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     \"Medium\" dose: &gt;264-440 mcg/day (110 mcg/puff: 2-4 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;text-align:justify;\">",
"     \"High\" dose: &gt;440 mcg/day (110 mcg/puff: &gt;4 puffs/day or 220 mcg/puff: &gt;2 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bronchopulmonary dysplasia, treatment: Infants: Some centers have used 2-4 puffs (44 mcg/puff) every 12 hours via a face mask and a spacer. One trial used fixed doses administered via a spacer and neonatal anesthesia bag (into ventilator, directly into nasopharyngeal endotracheal tube, or with a face mask) in 16 former preterm neonates (GA: &le;32 weeks; PNA: 28-60 days); chest radiograph score was improved compared to placebo; the treatment group had increased blood pressure compared to baseline; the authors conclude that the trial results do not support the use of fluticasone in oxygen-dependent patients with moderate BPD; exact dosing cannot be replicated in the U.S. with available products (Dugas, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Body weight:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     0.5-1.2 kg: 125 mcg every 12 hours for 3 weeks, followed by 125 mcg once daily for the 4",
"     <sup>",
"      th",
"     </sup>",
"     week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ge;1.2 kg: 250 mcg every 12 hours for 3 weeks, followed by 250 mcg once daily for the 4",
"     <sup>",
"      th",
"     </sup>",
"     week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Inhalation powder",
"     </b>",
"     (Flovent&reg; Diskus&reg;): Manufacturer's recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 4-11 years: Patients previously treated with bronchodilators alone or inhaled corticosteroids: Initial: 50 mcg twice daily; maximum dose: 100 mcg twice daily; may start higher initial dose in poorly controlled patients or in those who previously required higher doses of inhaled corticosteroids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients previously treated with bronchodilators alone: Initial: 100 mcg twice daily; maximum dose: 500 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients previously treated with inhaled corticosteroids: Initial: 100-250 mcg twice daily; maximum dose: 500 mcg twice daily; may start doses above 100 mcg twice daily in poorly controlled patients or in those who previously required higher doses of inhaled corticosteroids",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Patients previously treated with oral corticosteroids: Initial: 500-1000 mcg twice daily (select dose based on assessment of individual patient); maximum dose: 1000 mcg twice daily;",
"     <b>",
"      Note:",
"     </b>",
"     Inability to reduce oral corticosteroid therapy may indicate need for maximum fluticasone dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NIH Asthma Guidelines (NAEPP, 2007) (give in divided doses twice daily):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 5-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     \"Low\" dose: 100-200 mcg/day (50 mcg/puff: 2-4 puffs/day or 100 mcg/puff: 1-2 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     \"Medium\" dose: &gt;200-400 mcg/day (50 mcg/puff: 4-8 puffs/day or 100 mcg/puff: 2-4 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     \"High\" dose: &gt;400 mcg/day (50 mcg/puff: &gt;8 puffs/day or 100 mcg/puff: &gt;4 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     \"Low\" dose: 100-300 mcg/day (50 mcg/puff: 2-6 puffs/day or 100 mcg/puff: 1-3 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     \"Medium\" dose: &gt;300-500 mcg/day (50 mcg/puff: 6-10 puffs/day or 100 mcg/puff: 3-5 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     \"High\" dose: &gt;500 mcg/day (50 mcg/puff: &gt;10 puffs/day or 100 mcg/puff: &gt;5 puffs/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral (swallowed): Note:",
"     </b>",
"     Patients use an oral inhaler without a spacer and swallow the medication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Eosinophilic esophagitis: Optimal dose and dosing regimen are not established. Dosing from two more recent studies is presented.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     A randomized, double-blind, placebo-controlled trial (n=31) demonstrated efficacy by assessment of histologic remission (Konikoff, 2006): Children: 3-16 years: 440 mcg twice daily for 3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     A prospective, randomized trial (n=80) compared swallowed fluticasone to oral prednisone; a greater degree of improvement in histologic response was seen in the prednisone group; however, no difference in clinical response was observed between the two groups (Schaffer, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1-10 years: 220 mcg 4 times daily for 4 weeks, 220 mcg 3 times daily for 3 weeks, 220 mcg twice daily for 3 weeks, 220 mcg daily for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children and Adolescents: 11-18 years: 440 mcg 4 times daily for 4 weeks, 440 mcg 3 times daily for 3 weeks, 440 mcg twice daily for 3 weeks, 440 mcg daily for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     Use with caution; monitor patients closely;",
"     <b>",
"      Note:",
"     </b>",
"     Fluticasone is primarily eliminated via hepatic metabolism and serum concentrations may be elevated in patients with hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F242572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation, as propionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flovent&reg; HFA: 44 mcg/inhalation (10.6 g); 110 mcg/inhalation (12 g); 220 mcg/inhalation (12 g) [chlorofluorocarbon free; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, for oral inhalation, as propionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flovent&reg; Diskus&reg;: 50 mcg (60s); 100 mcg (60s); 250 mcg (60s) [contains lactose]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9349571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10495266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral inhalation: Rinse mouth with water (without swallowing) after inhalation to decrease chance of oral candidiasis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aerosol inhalation: Shake canister well for 5 seconds before each spray; use at room temperature. Inhaler must be primed before first use with four test sprays (spray into air away from face, shake well for 5 seconds between sprays) and primed again with one test spray if not used for &gt;7 days or if dropped. Use a spacer device for children &lt;8 years of age. Patient should contact pharmacy for refill when the dose counter reads \"020.\" Discard device when the dose counter reads \"000.\" Do not try to alter numbers on counter or remove the counter from the metal canister. Do not immerse canister into water (ie, do not use \"float test\" to determine contents).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Powder for oral inhalation: Flovent&reg; Diskus&reg;: Do not use with spacer device; do not exhale into Diskus&reg;; do not wash or take apart; activate and use Diskus&reg; in horizontal position",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral (swallowed):",
"     <b>",
"      Note:",
"     </b>",
"     This method of administration is for treatment of eosinophilic esophagitis only. Use metered dose inhaler. Do not use a spacer. Shake canister well for 5 seconds before each spray. Prime inhaler as outlined above. Actuate inhaler and spray medication into pharynx; swallow the medication (rather than inhale). Do not eat, drink, or rinse mouth for 30 minutes following administration (Konikoff, 2006; Schaefer, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10494944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flovent&reg; HFA: Store at controlled room temperature of 25&deg;C (77&deg;F) with mouthpiece down. Do not use or store near heat or open flame. Do not expose to temperatures &gt;120&deg;F. Do not puncture or incinerate. Discard device when the dose counter reads \"000.\"",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diskus&reg;: Store at controlled room temperature; keep dry; protect from direct heat or sunlight; discard Diskus&reg; 6 weeks (for 50 mcg strength) or 2 months (for 100 mcg and 250 mcg strengths) after opening moistureproof foil overwrap or when dose indicator reads \"0\" (whichever comes first);",
"     <b>",
"      Note:",
"     </b>",
"     Diskus&reg; device is not reusable.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F990184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;display:inline\">",
"     Oral inhalation: Long-term (chronic) control of persistent bronchial asthma;",
"     <b>",
"      not",
"     </b>",
"     indicated for the relief of acute bronchospasm. Also used to help reduce or discontinue oral corticosteroid therapy for asthma (FDA approved in ages &ge;4 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral (swallowed; using metered dose inhaler): Has been used for eosinophilic esophagitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9349564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Flovent&reg; may be confused with Flonase&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegro: Brand name for fluticasone [Israel], but also the brand name for frovatriptan [Germany]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegro [Israel] may be confused with Allegra and Allegra-D brand names for fexofenadine and fexofenadine/pseudoephedrine, respectively [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flovent [U.S., Canada] may be confused with Flogen brand name for naproxen [Mexico]; Flogene brand name for piroxicam [Brazil]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9349583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, fever, headache, malaise, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Gastrointestinal infection (including viral), gastrointestinal discomfort/pain, nausea, oral candidiasis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, articular rheumatism, muscle injury, musculoskeletal pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, cough, hoarseness/dysphonia, nasal congestion, rhinitis, sinusitis/sinus infection, throat irritation, upper respiratory tract inflammation/infection, viral respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Aggression, agitation, anaphylactic reaction (rare with both products; Diskus&reg; - some patients with severe milk allergy), angioedema, anxiety, aphonia, asthma exacerbation, behavioral changes (eg, hyperactivity and irritability in children; rare), bone mineral density decreased, bronchospasm (immediate and delayed), cataracts, chest tightness, Churg-Strauss syndrome, contusion, Cushingoid features, cutaneous hypersensitivity, depression, dyspnea, ecchymoses, eosinophilia, facial edema, growth velocity reduction in children/adolescents, HPA axis suppression, hyperglycemia, hypersensitivity reactions (immediate and delayed), laryngitis, migraine, muscle rigidity/stiffness/tightness, oropharyngeal edema, osteoporosis, paradoxical bronchospasm, pneumonia, restlessness, throat soreness, tooth discoloration, urticaria, vasculitis, wheeze",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10494376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluticasone or any component; primary treatment of status asthmaticus",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10494399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid using higher than recommended doses; suppression of HPA function, suppression of linear growth (ie, reduction of growth velocity), reduced bone mineral density, hypercorticism (Cushing's syndrome), hyperglycemia, or glucosuria may occur; these adverse effects (as well as intracranial hypertension) may occur with topical use and have been reported in pediatric patients. Use with extreme caution in patients with respiratory tuberculosis, untreated systemic infections, or ocular herpes simplex. Use with caution and monitor patients closely with hepatic dysfunction. Eosinophilic conditions (eosinophilia, vasculitic rash, cardiac complications, worsening pulmonary symptoms, and/or neuropathy) may occur and are usually associated with withdrawal or decrease of oral corticosteroids after the initiation of fluticasone (oral inhalation); a causal relationship by fluticasone has not been established. Increased IOP, glaucoma, and cataracts may occur with long-term use of inhaled corticosteroids.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10494388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after switching from systemic corticosteroids to aerosol steroids; several months may be required for full recovery of hypothalamic-pituitary-adrenal (HPA) axis function; patients receiving higher doses of systemic corticosteroids (eg, adults receiving &ge;20 mg of prednisone per day) may be at greater risk; during this period of HPA axis suppression, aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic glucocorticoid or mineralocorticoid activity needed to treat patients requiring stress doses (ie, patients with major stress such as trauma, surgery, infections, or other conditions associated with severe electrolyte loss). When used at high doses or for a prolonged time, hypercorticism and HPA axis suppression (including adrenal crisis) may occur; use with inhaled or systemic corticosteroids (even alternate-day dosing) may increase risk of HPA axis suppression. Acute adrenal insufficiency may occur with abrupt withdrawal after long-term use or with stress; withdrawal and discontinuation of corticosteroids should be done carefully; patients with HPA axis suppression may require doses of systemic glucocorticosteroids prior to, during, and after unusual stress (eg, surgery). Immunosuppression may occur; patients may be more susceptible to infections; avoid exposure to chickenpox and measles. Switching patients from systemic corticosteroids to aerosol steroids may unmask allergic conditions previously treated by the systemic steroid. Bronchospasm may occur after use of inhaled asthma medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Potent inhibitors of cytochrome P450 isoenzyme CYP3A4 (eg, ritonavir) may significantly increase fluticasone serum concentrations and result in systemic corticosteroid effects. Powder for oral inhalation (Flovent&reg; Diskus&reg;) contains lactose (milk proteins) which may cause allergic reactions in patients with severe milk protein allergy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9349607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9349606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of Corticosteroids (Orally Inhaled). Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F242569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9349575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed with systemic corticosteroids in animal reproduction studies. A decrease in fetal growth has not been observed with inhaled corticosteroid use during pregnancy. Inhaled corticosteroids are recommended for the treatment of asthma (most information available using budesonide) during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F990190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Check mucus membranes for signs of fungal infection; monitor growth in pediatric patients; monitor IOP with therapy &gt;6 weeks. Monitor for symptoms of asthma, FEV",
"     <sub>",
"      1",
"     </sub>",
"     , peak flow, and/or other pulmonary function tests. Assess HPA suppression in patients using potent topical steroids applied to a large surface area or to areas under occlusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F990188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10494964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral inhalation: Clinical effects are due to direct local effect rather than systemic absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Variable; may occur within 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum effect: 1-2 weeks or more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration after discontinuation: Several days or more",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10494985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 4.2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 91% to 99%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Via cytochrome P450 3A4 pathway to 17&beta;-carboxylic acid (inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral inhalation: Flovent&reg;: 30% of dose delivered from actuator; Flovent&reg; HFA: 30% lower than Flovent&reg;; Diskus&reg;: 18%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: 7.8 hours",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10495284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/33/12822?source=see_link\">",
"      see \"Fluticasone (oral inhalation): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if condition being treated persists or worsens; do not decrease dose or discontinue without physician approval. Avoid exposure to chicken pox or measles; if exposed, seek medical advice without delay. May cause headache. Notify physician immediately if allergic symptoms develop. Report signs of infection or change in vision to prescriber.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral inhalation: Report sore mouth or mouth lesions to physician; carefully read and follow the Patient's Instructions for Use leaflet that accompanies the product",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10495304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Flovent&reg; HFA does",
"     <b>",
"      not",
"     </b>",
"     contain CFCs as the propellant; Flovent&reg; HFA is packaged in a plastic-coated, moisture-protective foil pouch that also contains a desiccant; the desiccant should be discarded when the pouch is opened",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When using fluticasone oral inhalation to help reduce or discontinue oral corticosteroid therapy, begin prednisone taper after at least 1 week of fluticasone inhalation therapy; do not decrease prednisone faster than 2.5 mg/day on a weekly basis; monitor patients for signs of asthma instability and adrenal insufficiency; decrease fluticasone to lowest effective dose",
"     <b>",
"      after",
"     </b>",
"     prednisone reduction is complete. If bronchospasm with wheezing occurs after oral inhalation use, a fast-acting bronchodilator may be used; discontinue orally inhaled corticosteroid and initiate alternative chronic therapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Oral (swallowed) use: In the study by Schaffer that compared swallowed fluticasone to oral prednisone, systemic adverse effects occurred more frequently in the oral prednisone group; esophageal candidiasis occurred in 15% of patients using swallowed fluticasone (Schaffer, 2008).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dugas MA, Nguyen D, Frenette L, et al, \"Fluticasone Inhalation in Moderate Cases of Bronchopulmonary Dysplasia,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 115(5):566-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/29/25047/abstract-text/15833887/pubmed\" id=\"15833887\" target=\"_blank\">",
"        15833887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fok TF, Lam K, Dolovich M, et al, \"Randomised Controlled Study of Early Use of Inhaled Corticosteroid in Preterm Infants With Respiratory Distress Syndrome,\"",
"      <i>",
"       Arch Dis Child Fetal Neonatal Ed",
"      </i>",
"      , 1999, 80(3):203-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/29/25047/abstract-text/10212082/pubmed\" id=\"10212082\" target=\"_blank\">",
"        10212082",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Konikoff MR, Noel RJ, Blanchard C, et al, \"A Randomized, Double-Blind, Placebo-Controlled Trial of Fluticasone Propionate for Pediatric Eosinophilic Esophagitis,\"",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2006, 131(5):1381-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/29/25047/abstract-text/17101314/pubmed\" id=\"17101314\" target=\"_blank\">",
"        17101314",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ng PC, Fok TF, Liu F, et al, \"Effects of Inhaled Corticosteroids on Systemic Blood Pressure in Preterm Infants,\"",
"      <i>",
"       Biol Neonate",
"      </i>",
"      , 2004, 86(3):201-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/29/25047/abstract-text/15249756/pubmed\" id=\"15249756\" target=\"_blank\">",
"        15249756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schaffer ET, Fitzgerald JF, Molleston JP, et al, \"Comparison of Oral Prednisone and Topical Fluticasone in the Treatment of Eosinophilic Esophagitis: A Randomized Trial in Children,\"",
"      <i>",
"       Clin Gastroenterol Hepatol",
"      </i>",
"      , 2008, 6(2):165-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/29/25047/abstract-text/18237866/pubmed\" id=\"18237866\" target=\"_blank\">",
"        18237866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15933 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25047=[""].join("\n");
var outline_f24_29_25047=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349568\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349569\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990183\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12674645\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990189\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242572\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349571\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495266\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494944\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990184\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349564\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349583\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494376\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494399\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494388\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349607\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349606\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F242569\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9349575\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990190\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F990188\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494964\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10494985\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495284\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495304\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15933\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15933|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/3/30773?source=related_link\">",
"      Fluticasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/5/28756?source=related_link\">",
"      Fluticasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/45/32468?source=related_link\">",
"      Fluticasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?25/32/26120?source=related_link\">",
"      Fluticasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/33/12822?source=related_link\">",
"      Fluticasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44340?source=related_link\">",
"      Fluticasone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/54/15204?source=related_link\">",
"      Fluticasone (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/7/27764?source=related_link\">",
"      Fluticasone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_29_25048="Birth centers";
var content_f24_29_25048=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Birth centers",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/29/25048/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/29/25048/contributors\">",
"     Susan Stapleton, DNP, CNM, FACNM",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/29/25048/contributors\">",
"     Judith P Rooks, CNM, MPH, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/29/25048/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/29/25048/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/29/25048/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/29/25048/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/29/25048/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since 1989, approximately 1 percent of births annually in the United States have occurred in non-hospital settings. Of these, 67 percent were home births and 28 percent took place in birth centers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/1\">",
"     1",
"    </a>",
"    ]. For women thought to be at low risk for obstetrical complications, labor and delivery at a birth center can result in higher patient satisfaction, cost savings, and equivalent or better outcomes than in-hospital birth [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will provide a brief history of the development of birth centers in the United States and the evidence regarding the birth center model of care. Home birth is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20312?source=see_link\">",
"     \"Planned home birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HISTORY OF OUT-OF-HOSPITAL BIRTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;For most of the 20th century, out-of-hospital birth took place in the mother&rsquo;s home, maternity homes, clinics, or a birth room in a doctor's office. During the first half of this century, such sites served women who did not have access to, could not afford, or did not want, the services of physicians and acute care hospitals. During this era, the first nurse-midwifery services were established to provide care for the poor. Some examples are Kentucky's Frontier Nursing Service (FNS), New York City's Maternity Center Association (MCA), and Santa Fe's La Casita, which was operated by the Medical Mission Sisters.",
"   </p>",
"   <p>",
"    The proportion of births occurring in hospitals rose from 37 percent in 1935 to 97 percent in 1960, and reached 99 percent by the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/3\">",
"     3",
"    </a>",
"    ]. Several developments after World War II led to this change: (1) The GI Bill broadened opportunities for medical education, which resulted in doubling of the number of medical schools and new physicians; (2) the Hill Burton Act promoted the construction of community hospitals, which improved access to hospital care; (3) hospitals offered methods of pain relief in labor not available in the home; and (4) the expansion of employer-based health insurance and the creation of Medicaid provided insurance coverage for most pregnant women but only paid for maternity services provided by doctors and hospitals, not out-of-hospital births.",
"   </p>",
"   <p>",
"    As a result, birth moved from mostly in homes to mostly in hospitals, and from the care of mostly traditional midwives to care provided by physicians. Since childbirth in United States hospitals was attended exclusively by physicians, the profession of nurse-midwifery was not able to develop there as it did in other developed countries. By comparison, in Europe, where the profession of midwifery had been well-established since the 1700s, the movement of births from homes to hospitals included the movement of midwives into the hospitals.",
"   </p>",
"   <p>",
"    Other consequences of the shift in maternity care from home to hospital were that the needs of healthy mothers were not considered separately from the needs of mothers with medical or obstetrical problems, and there was little evaluation of the impact of hospitalization on mothers, babies, families, or society as a whole. The observation that the health of sick mothers and babies was improved by specialist care in the acute care hospital setting led to the establishment of the medical model of obstetrical care for all women. Scant attention was paid to the often quite different needs of the majority of women who were healthy and anticipating an uncomplicated childbirth.",
"   </p>",
"   <p>",
"    Reactions to increasing technological intervention in acute care hospitals began as early as the 1940s, when Grantly Dick Read, a British obstetrician considered to be the father of natural childbirth, published \"Childbirth Without Fear,\" in which he promoted his hypothesis that most of the pain in childbirth was caused by fear. Based in part on this work, a consumer-driven natural childbirth education movement developed and asked for maternity care with less medical intervention and more focus on the family. Hospitals tried to respond to this consumer demand by relaxing restrictions on family participation, but these changes were difficult to implement in the acute care setting. In the late 1960s, some upper middle-class women began opting for home birth in an effort to reclaim control of the natural physiological process of birth. Home births were unattended or attended by a new kind of lay-midwife, many of whom had been childbirth educators, Le Leche League leaders, nurses, or mothers who had been \"radicalized\" by their own bad hospital or good home birth experiences [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the 1970s, concern about the safety of unattended and lay-midwife-attended home births prompted the Maternity Center Association, a voluntary health agency in New York City, to establish a demonstration birth center in an affluent urban setting. It was designed and operated to provide professional nurse-midwifery care in collaboration with obstetrical specialists for women anticipating a normal pregnancy and birth. If that expectation changed, birth-center professionals referred or transferred the woman to the collaborating obstetrical specialist and hospital for further evaluation and appropriate care. Maternity Center Association has been reorganized as Childbirth Connections, which focuses on informing women about evidence-based maternity care [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BIRTH CENTER MODEL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A birth center was originally defined as any health facility, place, or institution that is not a hospital or in a hospital, where births are planned to occur away from the mother's usual residence following a normal uncomplicated pregnancy. This definition has been modified by the Commission for the Accreditation of Birth Centers (CABC) to include in-hospital birth centers that demonstrate autonomy in operation and separation from the acute care obstetrical unit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Philosophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The birth center philosophy maintains that pregnancy and birth are normal physiological, psychosocial, and economic events within a family until proven otherwise. In general, the atmosphere of birth centers is relaxed, there are few routines, and the environment is more like a home than a hospital. Women wear their own clothes; control who will be with them during labor and birth; take showers or baths; and eat, drink and walk or change positions freely. It is rare for the mother and baby to be separated after the birth. The newborn examination is done on the mother's bed and used as an opportunity to explain newborn behavior and answer questions.",
"   </p>",
"   <p>",
"    If complications that require medical or surgical intervention arise, the care of the woman or newborn is transferred to the collaborating physician, most often an obstetrical specialist or neonatologist at the collaborating hospital. Compliance with strict transfer criteria has resulted in good outcomes for these patients, even when intrapartum complications occur [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Birth center care providers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Birth centers are typically staffed by midwives. Certified nurse-midwives (CNMs) attended 51 percent of births that occurred in birth centers in 2010; other midwives (some of whom are certified professional midwives [CPMs]) attended 41 percent, and physicians attended 4.8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/1\">",
"     1",
"    </a>",
"    ]. This represents a slight increase by midwives other than CNMs and a slight decrease by CNMs and physicians as compared to previous years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Criteria for eligibility for birth center care",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1974, in preparation for its demonstration Childbearing Center, the Maternity Center Association formed a Research Advisory Committee of professionals representing obstetrics, neonatology, nursing, nurse-midwifery, and public health to develop criteria for low risk pregnancy and childbirth based on the best evidence available at that time. Blue",
"    <span class=\"nowrap\">",
"     Cross/Blue",
"    </span>",
"    Shield of Greater New York and New York State evaluated the use and outcome of these risk criteria over a 16-month period, and validated their use. Little has changed from the initial criteria defining a low risk pregnancy and birth [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An evidence-based, rigorous screening process begins when the woman enrolls in a birth center for prenatal care, or sometimes with an initial phone call. Women who are candidates for birth center care should not have medical or obstetric conditions that increase the risk of intrapartum complications. They are generally healthy, not obese, and unlikely to use tobacco or illicit drugs. Women who have had a previous cesarean delivery are at higher risk of serious intrapartum complications and therefore are usually excluded from birth center care [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/8\">",
"     8",
"    </a>",
"    ], although, this is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Careful screening continues at every prenatal visit using predefined risk criteria that are mutually agreed upon by the birth center care providers and collaborating physicians. Women who experience pregnancy complications, such as preeclampsia, preterm labor, or significant anemia, are required to give birth in the hospital, where their care is often managed collaboratively by a midwife and obstetrician team.",
"   </p>",
"   <p>",
"    Criteria by which a pregnancy is judged to be low risk at the onset of labor include having followed a normal, uncomplicated prenatal course as determined during adequate care and lack of any reason to anticipate a serious complication during labor, as defined by reasonable and generally accepted criteria. There should be only one fetus, no serious obstetrical or medical conditions, no previous cesarean delivery, cephalic presentation and neither pre- or postterm onset of labor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Scope of care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Birth center care encompasses the antepartum, intrapartum, and",
"    <span class=\"nowrap\">",
"     postpartum/neonatal",
"    </span>",
"    periods. Since the woman becomes familiar with the birth center and its personnel during her pregnancy, there is no need for a \"hospital visit\" or a \"meet the provider\" night to view where the birth will take place and meet the people who might be involved.",
"   </p>",
"   <p>",
"    Antepartum care provided at a birth center is more time and education intensive than traditional physician-led pregnancy care. In addition to the usual components of antepartum care, birth center care focuses on building the childbearing couple&rsquo;s confidence in having a normal birth and caring for their newborn. Clients are members of the health care team and participate in making decisions about their care. All of the standard prenatal tests are offered to women by their birth center providers, as indicated, with discussion of the risks and benefits of each test.",
"   </p>",
"   <p>",
"    Birth center care during labor and birth continues this time-intensive, one-on-one approach. In accordance with a large body of research indicating that intermittent auscultation of the fetal heart rate is appropriate and safe for low-risk women, birth centers use intermittent auscultation rather than continuous electronic fetal monitoring to monitor the status of the fetus during labor. If a condition indicating the need for continuous electronic monitoring occurs, the mother is transferred to a hospital, as she is no longer appropriate for out-of-hospital birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=see_link\">",
"     \"Intrapartum fetal heart rate assessment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some birth centers offer narcotic analgesics for pain relief during labor, although pharmacologic pain relief is rarely needed and used sparingly only after nonpharmacologic methods have been tried. A few birth centers provide",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    for labor analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/44/38601?source=see_link\">",
"     \"Nonpharmacological approaches to management of labor pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epidural analgesia is not offered in birth centers because of the risks involved with its use and the need for additional medical interventions (eg, intravenous infusions, continuous electronic fetal monitoring, frequent blood pressure monitoring, urinary bladder catheterization,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    augmentation, and an increased need for operative vaginal deliveries) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Operative vaginal deliveries are not performed in birth centers. Need for an epidural or operative vaginal birth indicates the need for transfer to a hospital. Episiotomies are rarely performed [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The midwife or other professional care provider monitors the condition of the mother and baby continuously during the immediate postpartum and neonatal periods, while also providing appropriate privacy for parents to interact with their newborns. Follow-up postpartum and newborn care may include telephone calls, home visits, and breastfeeding support, as well as an office visit within the first two weeks. All women have at least a telephone call and visit. Women who were transferred to a hospital during labor may be provided routine birth center follow-up, according to their preference.",
"   </p>",
"   <p>",
"    In the mid-1980s National Birth Center Study (NBCS, discussed below), virtually all of the women who were not transferred to a hospital during labor or soon after giving birth had one or more home or office visits during the four to six weeks postpartum period. Birth center staff visited 40 percent of the women in their home, including 4 percent who were visited within 24 hours of the birth. Most of the home visits occurred on the second or third postpartum day. Sixty-three percent of the women had at least one home or office visit within the first three postpartum days. Most women who had home visits had only one; 9 percent had two or more. Some birth centers provide primary care to newborns during the neonatal period or the entire first year of life. Birth centers operated by family practice physicians provided care to the infants of two-thirds of their clients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Birth center clinicians provide thorough information with extensive discussion of care choices. Parents are asked to sign a document asserting that they understand the risks and benefits of labor and delivery at a birth center and have chosen to labor and give birth in the birth center (",
"    <a class=\"graphic graphic_form graphicRef72798 graphicRef53826 graphicRef65561 \" href=\"UTD.htm?42/30/43498\">",
"     form 1A-C",
"    </a>",
"    ). This discussion and consent form should review unforeseen events that can occur during any childbirth, and how they might be handled at the birth center as compared to a hospital. The consent process includes discussion of a list of specific complications that would require a prenatal referral to the collaborating physician",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transfer of the mother or baby to a hospital. Arrangements for access to a specialist and in-hospital care for mother and newborn, if needed, should be reviewed periodically during antenatal care, and the approximate time it may take to affect a transfer to a hospital in emergent situations should be discussed. Birth centers conduct regular emergency drills, including drills with area emergency teams, and thus can tell families how a necessary emergency transfer would proceed. All birth centers know their average emergency and nonemergency transport times, and how they vary with the time of day, traffic, and",
"    <span class=\"nowrap\">",
"     weather/road",
"    </span>",
"    conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Licensing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Public Health Association (APHA) has published official \"Guidelines for the Regulation of Birth Centers,\" which are used by states to write regulations for licensing birth centers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/16\">",
"     16",
"    </a>",
"    ]. As of 2011, 82 percent of states in the United States licensed birth centers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Standards and accreditation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accreditation is a voluntary process that includes self evaluation of all of the essential elements of the organization and management of birth center quality of care. It is designed as an educational process and is similar to that used to accredit hospitals and other health care facilities. The Commission for the Accreditation of Birth Centers (CABC) accreditation process provides birth centers with a benchmark for comparing their own performance with national standards and with other exemplary birth centers. Accredited birth centers are expected to comply with national standards and are held accountable for their care and outcomes by their peers. As of late 2012, 55 birth centers were accredited by the CABC, and 5 other birth centers were in the accreditation process [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/18\">",
"     18",
"    </a>",
"    ]. Four states either require CABC accreditation for licensure or waive site visits by the regulatory agency when CABC site visits are conducted. One state without birth center licensure requires CABC accreditation for Medicaid reimbursement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Medicolegal liability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Birth centers have been subject to the same volatility in the liability insurance market that has affected other facilities that provide care during birth. In 1985, the liability insurance carrier for birth centers and nurse-midwives withdrew from the obstetrical insurance market, thereby forcing one-fourth of all birth centers operating at that time to close. In 2012, three national carriers and several regional carriers offered medical liability insurance for birth centers; birth center members of AABC reported that the increase in premiums had stabilized [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The AABC periodically surveys its members for information on claims ever filed and outcomes of those claims. Thirty-five centers in 13 states reported liability data in 2010. Ten reported no claims against the center for at least the previous 20 years. Information was provided about 14 claims against birth centers; 1 was dismissed, 2 were dropped, 10 were settled out of court, and a jury decided in favor of the birth center in one case. Two birth centers that reported claims did not provide other information [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to a comprehensive Quality Improvement Program, AABC works with liability insurance carriers that insure midwives and birth centers to reduce liability risks by reviewing claims that have been filed and offers risk reduction education based on what is learned by those reviews. One goal is to facilitate and ensure complete documentation of the care provided, the plan for management of care, formal and informal consultations, referrals, and transfers. Frequent and regular emergency simulation drills and careful evaluation of staff performance and birth center emergency procedures are also important for risk management. CABC requires accredited birth centers to conduct medical emergency drills quarterly, document evaluation of their performance, and follow up any identified deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     EVIDENCE SUPPORTING THE BIRTH CENTER MODEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of out-of-hospital birth has always been paramount to those who support or oppose it. &nbsp;In 1982, The Institute of Medicine (IOM) of the National Academy of Sciences (NAS) published the work of a committee of experts, &ldquo;Research Issues in the Assessment of Birth Settings,&rdquo; which concluded that &ldquo;reliable information about the safety and efficacy of different birth settings, the psychological benefits of different practices, and the difference in economic costs of the alternatives is lacking.&rdquo; This statement provided the impetus for the first National Birth Center Study (NBCS I) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/6,15,22,23\">",
"     6,15,22,23",
"    </a>",
"    ]. In May 2007, ACOG acknowledged the safety of births in freestanding birth centers that meet the standards of relevant accrediting organizations, eg, the Commission for the Accreditation of Birth Centers (CABC) and the Accreditation Association for Ambulatory Health Care.",
"   </p>",
"   <p>",
"    No large randomized controlled trial (RCT) has been conducted to compare birth center outcomes to outcomes of care in hospitals. Most women are adamant about their preference for a hospital or out-of-hospital birth, making RCTs to compare the safety of various birth settings not feasible. Other research designs have been used to provide evidence on the safety of various birth settings. The best available data on birth centers are from the NBCS I (1985-1987) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/6,15,22,23\">",
"     6,15,22,23",
"    </a>",
"    ] and the NBCS II (2007-2010) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/24\">",
"     24",
"    </a>",
"    ]. Major findings and conclusions of both studies are summarized below. No study has ever reported poorer outcomes among women cared for in United States birth centers as compared with United States hospitals.",
"   </p>",
"   <p>",
"    Systematic reviews of randomized trials and other controlled studies have been used to evaluate many elements of childbirth care. Many interventions used almost routinely in labor and birth in some United States hospitals are overused, and overuse has been associated with complications and poor outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/25\">",
"     25",
"    </a>",
"    ]. Many women choose to give birth in birth centers to avoid unnecessary use of those procedures and routines. At the same time, research has supported the value of maternity care elements that are hallmarks of birth center care, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antepartum pregnancy and childbirth education (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10311?source=see_link\">",
"       \"Preparation for labor and childbirth\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Caregiver support during labor and birth (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22855?source=see_link\">",
"       \"Continuous intrapartum support\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nonpharmacological management of labor pain (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/44/38601?source=see_link\">",
"       \"Nonpharmacological approaches to management of labor pain\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Education and support for initiation and continuation of breastfeeding (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"       \"Infant benefits of breastfeeding\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H137349612\">",
"    <span class=\"h2\">",
"     The National Birth Center Study",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     The National Birth Center Study, 1985-1987",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Association of Childbearing Centers conducted a large prospective study of birth center care in the United States during the mid-1980s: the NBCS I [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/6,15,22,23\">",
"     6,15,22,23",
"    </a>",
"    ]. The NBCS I followed the pregnancies of almost 18,000 women who registered for care at 84 birth centers in 35 states throughout the United States from 1985 to 1987. Certified nurse-midwives (CNMs) were the principal prenatal care providers for 81 percent of the women in the NBCS and managed the labors of 79 percent of the women [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The study was conducted to: (1) determine whether birth centers were safe, and (2) describe women who use birth centers, the care they receive in birth centers, and the outcomes of that care, including outcomes for women and newborns transferred to the hospitals during labor or shortly after birth in a birth center.",
"   </p>",
"   <p>",
"    Data analysis was done on an intent-to-treat basis. Major findings of this study are summarized below [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/6,15,22,23\">",
"     6,15,22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transfers out of birth center care during pregnancy before labor and during labor or soon after birth:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      14 percent of women who began prenatal care at a birth center developed a complication that precluded out-of-hospital birth. Almost 90 percent of those complications occurred during the third trimester; postterm pregnancy was the most common reason.",
"     </li>",
"     <li>",
"      12 percent of the women admitted to birth centers in labor were transferred to hospitals before giving birth; 4 percent of the mothers and 4 percent of the newborns were transferred to hospitals because of postpartum or newborn complications.",
"     </li>",
"     <li>",
"      Only 2.4 percent of all transfers were emergencies. The most common reasons for intrapartum transfers were failure to progress (43 percent), meconium stained amniotic fluid (11 percent), and non-reassuring fetal heart rate (8 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cesarean deliveries:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The cesarean delivery rate for women who planned birth center delivery was significantly lower than the national average during the study period 1985 to 1987 (4.4 versus 24.4 percent)",
"     </li>",
"     <li>",
"      The cesarean rate for women who planned birth center delivery was also lower than the 8.4 percent rate for",
"      <strong>",
"       low risk",
"      </strong>",
"      women delivering in hospitals in 1980 [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complications - The NBCS investigators and Medical Advisory Committee developed a system to summarize the seriousness and urgency of 28 specific intrapartum and immediate postpartum and neonatal complications that might be experienced by women and babies during care in birth centers. Each complication was assigned a Complication Seriousness Score between 1 and 3 to indicate its seriousness regarding the risk of death or permanent impairment and a Complication Urgency Score between 1 and 3 to reflect the need for rapid transfer to hospital care. Complications with a score of 3 on both scales, eg, thick meconium, sustained nonreassuring fetal heart rate pattern, abruptio placenta, eclampsia, prolapsed umbilical cord, severe shoulder dystocia, and neonatal cyanosis, were categorized as serious emergencies. Sixteen percent of women and newborns were transferred to hospitals during labor or after the birth; 9 percent of those transferred had serious complications; 7.9 percent of all women in the study, or their newborns, experienced serious complications [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/6,15\">",
"       6,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mortality:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There were no maternal deaths.",
"     </li>",
"     <li>",
"      There were 15 intrapartum and neonatal deaths",
"      <span class=\"nowrap\">",
"       (1.3/1000",
"      </span>",
"      births), seven due to lethal congenital anomalies. The corrected intrapartum and neonatal mortality rate was",
"      <span class=\"nowrap\">",
"       0.7/1000",
"      </span>",
"      births [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/6,15\">",
"       6,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies of low-risk women delivering in three major United States hospitals during the same time period reported intrapartum plus neonatal mortality rates of 1.0 to",
"      <span class=\"nowrap\">",
"       4.3/1000",
"      </span>",
"      births [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/6,15\">",
"       6,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The total mortality rate for postterm pregnancies was slightly higher for births begun in birth centers than for postterm pregnancies managed in hospitals",
"      <span class=\"nowrap\">",
"       (2.3/1000",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       2.1/1000).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breastfeeding - Birth center mothers had a higher rate of breastfeeding than the national average at that time (78 percent versus 53 to 56 percent). Seventy-eight percent of birth center mothers breastfed their infants for at least four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Satisfaction - Almost 99 percent of birth center mothers said they would recommend the birth center to a friend.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6019821\">",
"    <span class=\"h3\">",
"     The National Birth Center Study II, 2007 to 2010",
"    </span>",
"    &nbsp;&mdash;&nbsp;NBCS II was a prospective cohort study that analyzed data collected through the American Association of Birth Centers&rsquo; (AABC) online data registry and described the care and outcomes for 15,574 women who were planning, and eligible for, intrapartum admission to birth centers at the onset of labor. Participants received care in 79 midwifery-led birth centers in 33 states. The major findings are strikingly similar to the results found in NBCS I, which was conducted 22 years earlier. Clinical outcomes and intrapartum transfer rates were nearly the same during the two study periods. This consistency in key outcomes speaks to the durability of the birth center model of care over time despite consistent increases in rates of cesarean births and other obstetric interventions nationwide between the two time periods [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transfers out of birth center care during pregnancy, before and during labor or soon after birth:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A medical or obstetrical problem developed in 14 percent of women who entered prenatal care planning a birth center birth and made them ineligible for out-of-hospital birth. The most common problems were post-dates and malpresentation (10.7 and 10.4 percent, respectively, of all antepartum referrals).",
"     </li>",
"     <li>",
"      Of 15,574 women who planned and were eligible for birth center birth at the onset of labor, 4.5 percent were referred to hospitals before being admitted to the birth center in labor. The most common reasons for preadmission intrapartum referral were term rupture of membranes without labor (20.4 percent of referrals), patient choice (10.0 percent), and malpresentation (9.1 percent).",
"     </li>",
"     <li>",
"      Of the 14,881 women who were admitted to the birth center in labor, 12.4 percent were transferred to hospitals during labor after admission, 64 percent of these transfers were for prolonged labor or arrest of labor; 2.4 percent of mothers were transferred to hospitals postpartum, 68 percent of these transfers were for postpartum hemorrhage. In addition, 2.6 percent of newborns were transferred to hospitals after being born in the birth center; most of these transfers were for respiratory problems. Overall, 1 percent of transfers were considered emergent by the provider (0.4 percent of mothers and 0.6 percent of newborns).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Operative deliveries:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among women admitted to the birth centers in labor, 6 percent had a primary cesarean delivery and 1 percent had an operative vaginal delivery. The overall cesarean delivery rate for all low-risk women giving birth in the United States in 2007 was 26.5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mortality:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      There were no maternal deaths.",
"     </li>",
"     <li>",
"      The intrapartum fetal mortality rate for women admitted to the birth centers in labor was",
"      <span class=\"nowrap\">",
"       0.47/1000",
"      </span>",
"      and the neonatal mortality rate was",
"      <span class=\"nowrap\">",
"       0.40/1000,",
"      </span>",
"      excluding anomalous infants. These rates are comparable to those in the NBCS I and to rates in other studies of low-risk women planning to give birth in hospitals [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/27-32\">",
"       27-32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2963016\">",
"    <span class=\"h3\">",
"     Limitations of these studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The birth centers that participated in both NBCS I and II may not be representative of all birth centers operating in the United States, as only 53 percent of the birth centers participated in NBCS I.&nbsp;Five birth centers were excluded because site visits found that they had not enrolled all of their clients in the study or information from clinical records of a sample of their clients was insufficiently consistent with data they had submitted.",
"    <br/>",
"   </p>",
"   <p>",
"    NBCS II reported outcomes of 79 birth centers that are members of AABC and voluntarily contribute data to an online data registry. They represent 32 percent of all United States birth centers. Participating in the registry may signify a level of organization, adherence to standards, and quality assurance that may not exist in all birth centers.",
"   </p>",
"   <p>",
"    CNMs were the primary care providers in 80 percent of the birth centers that participated in NBCS II; certified professional midwives (CPMs) or licensed midwives (LMs) who are not CPMs were the primary providers in 14 percent of the centers, and CNMs and CPMs shared responsibility for primary care in 6 percent of them. The relative safety of births attended by CNMs as compared to CPMs was not evaluated.",
"   </p>",
"   <p>",
"    The impact of birth centers operating outside an infrastructure of licensure, national standards, and an accreditation mechanism may be different from those reported in NBCS I and II.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several prospective and retrospective observational studies and small randomized trials of care provided in freestanding birth centers, maternity homes, or low-risk maternity units in the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], Germany [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/35\">",
"     35",
"    </a>",
"    ], Norway [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/36\">",
"     36",
"    </a>",
"    ], Sweden [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/35,37,38\">",
"     35,37,38",
"    </a>",
"    ], Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/39\">",
"     39",
"    </a>",
"    ], Brazil [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/40\">",
"     40",
"    </a>",
"    ], Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/41-43\">",
"     41-43",
"    </a>",
"    ], and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. These studies have generally demonstrated that if patients are appropriately selected, birth centers are associated with perinatal outcomes comparable to, or better than, those for in-hospital care, with high rates of patient satisfaction and lower rates of medical and operative intrapartum intervention. Two systematic reviews have also affirmed the safety and benefits of birth center care for low-risk pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study published in 1992 attempted to separate the impact of the birth environment from that of the primary care provider by comparing the outcome of midwifery care provided to 2000 low risk women in a hospital to the outcomes of midwifery care provided to low risk women in the NBCS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/49\">",
"     49",
"    </a>",
"    ]. Women who labored in both sites experienced similar rates of antepartum and intrapartum complications, but those whose care was managed by midwives in hospitals were more likely to have obstetric interventions during labor and birth, such as continuous electronic fetal monitoring, intravenous hydration, episiotomy, and lithotomy position for birth. Women giving birth to their first child in the hospital with CNMs were significantly less likely to have an intact perineum (23 versus 30 percent). Cesarean delivery was less common in women who began their intrapartum care in birth centers compared to women who had midwifery care in hospitals (4.4 versus 9.5 percent). Major neonatal outcomes were similar for both groups, but some complications were much more common during midwife-attended births in hospitals, eg, fetal distress (6.6 versus 1.8 percent), cord prolapse (0.2 versus 0.03 percent), and difficulty establishing neonatal respirations (1.1 versus 0.4 percent). This study and similar findings from a trial in the Norway, in which women were randomly assigned to in-hospital maternity care on a midwife-led unit, usual obstetrical care unit, or specialized perinatal unit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/50\">",
"     50",
"    </a>",
"    ], suggest that the hospital environment results in more interventions irrespective of the provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14173429\">",
"    <span class=\"h2\">",
"     Studies comparing the costs of maternity care in birth centers versus hospital",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined the cost of care provided in birth centers compared to hospitals, including costs associated with transfer for a hospital delivery. These studies have consistently found that birth center care is associated with cost savings of 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/44,45,51\">",
"     44,45,51",
"    </a>",
"    ]. Some of this difference in cost appears to be related to less use of resources and procedures, eg, induction of labor, epidurals, opioid analgesia, continuous electronic fetal monitoring, hospital stays and neonatal intensive care in the birth center collaborative model of care versus the traditional physician-based model [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/44\">",
"     44",
"    </a>",
"    ]. The AABC estimates that &ldquo;if even 10 percent (400,000) of the approximately 4 million women who give birth in the United States each year delivered their babies in birth centers, the savings in facility fee payments alone would be at least $2.6 billion&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25048/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The birth center philosophy maintains that pregnancy and birth are normal physiological, psychosocial, and economic events within a family. Birth center midwives provide care at birth centers in settings that are relaxed, more like a home than a hospital, and minimize routines in favor of individualization. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Philosophy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Birth center care providers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Scope of care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women planning to deliver at a birth center should be at low risk of developing maternal or",
"      <span class=\"nowrap\">",
"       fetal/neonatal",
"      </span>",
"      complications. A pregnancy is not considered low risk if the mother has a past history of serious obstetrical or medical conditions, the prenatal course deviates from normal, labor occurs preterm or postterm, or the birth is expected to be complicated (eg, malpresentation). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Criteria for eligibility for birth center care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Birth center midwives can identify women who are at low risk for obstetrical complications and serve them safely in this non-hospital setting. Birth centers provide care for these women at lower cost than care in hospitals and obtain maternal and neonatal outcomes that are comparable to those for low risk women cared for by physicians and nurses in hospitals. Birth center care is associated with higher levels of patient satisfaction and lower rates of many interventions, including cesarean deliveries. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Evidence supporting the birth center model'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Accreditation is not required to operate in all jurisdictions,&nbsp;but indicates that a birth center has met a high standard of evidence-based and widely recognized benchmarks for maternity care, neonatal care, business operations, and safety. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Standards and accreditation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/1\">",
"      Births: Final data for 2010. Natl Vital Stat Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/2\">",
"      Swartz W, Jackson D, Lang J, et al. The BirthPlace collaborative practice model: results from the San Diego Birth Center Study. Prim Care Update Ob Gyns 1998; 5:207.",
"     </a>",
"    </li>",
"    <li>",
"     Rooks, JP. Midwifery and Childbirth in America. Temple University Press, Philadelphia 1997. p.35.",
"    </li>",
"    <li>",
"     www.childbirthconnections.org. (Accessed on April 11, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/5\">",
"      DeJong RN Jr, Shy KK, Carr KC. An out-of-hospital birth center using university referral. Obstet Gynecol 1981; 58:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/6\">",
"      Rooks JP, Weatherby NL, Ernst EK, et al. Outcomes of care in birth centers. The National Birth Center Study. N Engl J Med 1989; 321:1804.",
"     </a>",
"    </li>",
"    <li>",
"     Blue Cross and Blue Shield of Greater New York. Maternity Center Association's Childbearing Center: 1976-1977 Cost Analysis. Health Affairs Research, New York 1978.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/8\">",
"      Lieberman E, Ernst EK, Rooks JP, et al. Results of the national study of vaginal birth after cesarean in birth centers. Obstet Gynecol 2004; 104:933.",
"     </a>",
"    </li>",
"    <li>",
"     The Commission for the Accreditation of Birth Centers. Policy regarding vaginal birth after cesarean section in accredited birth centers. May 2010.",
"    </li>",
"    <li>",
"     The American Association of Birth Centers. VBAC Position Paper, January 2008. file://www.birthcenters.org/about-aabc/position-statements/vbac-study. (Accessed on April 04, 2012).",
"    </li>",
"    <li>",
"     Personal communication. Mike Civitello, Product Sales Manager. Porter Instrument Division, Parker Hannifin Corporatio, 245 Township Line Rd, Hatfield, PA 19440, USA.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/12\">",
"      Lieberman E, O'donoghue C. Unintended effects of epidural analgesia during labor: a systematic review. Am J Obstet Gynecol 2002; 186:S31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/13\">",
"      Mayberry LJ, Clemmens D, De A. Epidural analgesia side effects, co-interventions, and care of women during childbirth: a systematic review. Am J Obstet Gynecol 2002; 186:S81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/14\">",
"      Viswanathan M, Hartmann K, Palmieri R, et al. The use of episiotomy in obstetrical care: a systematic review. Evid Rep Technol Assess (Summ) 2005; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/15\">",
"      Rooks JP, Weatherby NL, Ernst EK. The National Birth Center Study. Part III--Intrapartum and immediate postpartum and neonatal complications and transfers, postpartum and neonatal care, outcomes, and client satisfaction. J Nurse Midwifery 1992; 37:361.",
"     </a>",
"    </li>",
"    <li>",
"     American Public Health Association. Guidelines for Licensing and Regulating Birth Centers. American Journal of Public Health 1983; 73.",
"    </li>",
"    <li>",
"     Commission for the Accreditation of Birth Centers 2012. file://www.birthcenteraccreditation.org/find-accredited-birth-centers/. (Accessed on March 23, 2012).",
"    </li>",
"    <li>",
"     Personal Communication, Kate Bauer, Executive Director, The American Association of Birth Centers, March 2012.",
"    </li>",
"    <li>",
"     American Association of Birth Centers. Uniform Data Set Data Registry 2010.",
"    </li>",
"    <li>",
"     Commission for the Accreditation of Birth Centers. Indicators for Compliance with Standards 2010.",
"    </li>",
"    <li>",
"     News, Birth 2007; 34:352.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/22\">",
"      Rooks JP, Weatherby NL, Ernst EK. The National Birth Center Study. Part I--Methodology and prenatal care and referrals. J Nurse Midwifery 1992; 37:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/23\">",
"      Rooks JP, Weatherby NL, Ernst EK. The National Birth Center Study. Part II--Intrapartum and immediate postpartum and neonatal care. J Nurse Midwifery 1992; 37:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/24\">",
"      Stapleton SR, Osborne C, Illuzzi J. Outcomes of care in birth centers: demonstration of a durable model. J Midwifery Womens Health 2013; 58:3.",
"     </a>",
"    </li>",
"    <li>",
"     Sakala C, Corry MP. Evidence-Based Maternity Care: What It Is and What It Can Achieve. Childbirth Connection, the Reforming States Group, and the Milbank Memorial Fund. October 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/26\">",
"      Menacker F. Trends in cesarean rates for first births and repeat cesarean rates for low-risk women: United States, 1990-2003. Natl Vital Stat Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/27\">",
"      Birthplace in England Collaborative Group, Brocklehurst P, Hardy P, et al. Perinatal and maternal outcomes by planned place of birth for healthy women with low risk pregnancies: the Birthplace in England national prospective cohort study. BMJ 2011; 343:d7400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/28\">",
"      Evers AC, Brouwers HA, Hukkelhoven CW, et al. Perinatal mortality and severe morbidity in low and high risk term pregnancies in the Netherlands: prospective cohort study. BMJ 2010; 341:c5639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/29\">",
"      Mathews TJ, MacDorman MF. Infant mortality statistics from the 2007 period linked birth/infant death data set. Natl Vital Stat Rep 2011; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/30\">",
"      Pasupathy D, Wood AM, Pell JP, et al. Time of birth and risk of neonatal death at term: retrospective cohort study. BMJ 2010; 341:c3498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/31\">",
"      Begley C, Devane D, Clarke M, et al. Comparison of midwife-led and consultant-led care of healthy women at low risk of childbirth complications in the Republic of Ireland: a randomised trial. BMC Pregnancy Childbirth 2011; 11:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/32\">",
"      Janssen PA, Saxell L, Page LA, et al. Outcomes of planned home birth with registered midwife versus planned hospital birth with midwife or physician. CMAJ 2009; 181:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/33\">",
"      Reddy K, Reginald PW, Spring JE, et al. A free-standing low-risk maternity unit in the United Kingdom: does it have a role? J Obstet Gynaecol 2004; 24:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/34\">",
"      David M, von Schwarzenfeld HK, Dimer JA, Kentenich H. Perinatal outcome in hospital and birth center obstetric care. Int J Gynaecol Obstet 1999; 65:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/35\">",
"      Gottvall K, Grunewald C, Waldenstr&ouml;m U. Safety of birth centre care: perinatal mortality over a 10-year period. BJOG 2004; 111:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/36\">",
"      Schmidt N, Abelsen B, &Oslash;ian P. Deliveries in maternity homes in Norway: results from a 2-year prospective study. Acta Obstet Gynecol Scand 2002; 81:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/37\">",
"      Waldenstr&ouml;m U, Nilsson CA, Winbladh B. The Stockholm birth centre trial: maternal and infant outcome. Br J Obstet Gynaecol 1997; 104:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/38\">",
"      Waldenstr&ouml;m U, Nilsson CA. Experience of childbirth in birth center care. A randomized controlled study. Acta Obstet Gynecol Scand 1994; 73:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/39\">",
"      Morano S, Cerutti F, Mistrangelo E, et al. Outcomes of the first midwife-led birth centre in Italy: 5 years' experience. Arch Gynecol Obstet 2007; 276:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/40\">",
"      Campos SE, Lana FC. [Results of childbirth care at a birthing center in Belo Horizonte, Minas Gerais, Brazil]. Cad Saude Publica 2007; 23:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/41\">",
"      Waldenstr&ouml;m U, Nilsson CA. A randomized controlled study of birth center care versus standard maternity care: effects on women's health. Birth 1997; 24:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/42\">",
"      Byrne JP, Crowther CA, Moss JR. A randomised controlled trial comparing birthing centre care with delivery suite care in Adelaide, Australia. Aust N Z J Obstet Gynaecol 2000; 40:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/43\">",
"      Tracy SK, Dahlen H, Caplice S, et al. Birth centers in Australia: a national population-based study of perinatal mortality associated with giving birth in a birth center. Birth 2007; 34:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/44\">",
"      Jackson DJ, Lang JM, Swartz WH, et al. Outcomes, safety, and resource utilization in a collaborative care birth center program compared with traditional physician-based perinatal care. Am J Public Health 2003; 93:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/45\">",
"      Eakins PS. Free-standing birth centers in California. Program and medical outcome. J Reprod Med 1989; 34:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/46\">",
"      Garite TJ, Snell BJ, Walker DL, Darrow VC. Development and experience of a university-based, freestanding birthing center. Obstet Gynecol 1995; 86:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/47\">",
"      Hodnett ED, Downe S, Walsh D. Alternative versus conventional institutional settings for birth. Cochrane Database Syst Rev 2012; 8:CD000012.",
"     </a>",
"    </li>",
"    <li>",
"     Stewart, M, McCandlish, R, Henderson, J, and Brocklehurst, P. Report of a Structured Review of Birth Centre Outcomes. National Perinatal Epidemiology Unit, Oxford University, December, 2004. (Revised July, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/49\">",
"      Fullerton JT, Severino R. In-hospital care for low-risk childbirth. Comparison with results from the National Birth Center Study. J Nurse Midwifery 1992; 37:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25048/abstract/50\">",
"      Bernitz S, Rolland R, Blix E, et al. Is the operative delivery rate in low-risk women dependent on the level of birth care? A randomised controlled trial. BJOG 2011; 118:1357.",
"     </a>",
"    </li>",
"    <li>",
"     Health Insurance Association of America. Research Bulletin: The Cost of Maternity care in the United States, Washington DC, 1989.",
"    </li>",
"    <li>",
"     American Association of Birth Centers. Birth Center Savings. Perkiomenville, PA 2010.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4456 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-221.179.173.170-189A616C48-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25048=[""].join("\n");
var outline_f24_29_25048=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HISTORY OF OUT-OF-HOSPITAL BIRTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BIRTH CENTER MODEL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Philosophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Birth center care providers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Criteria for eligibility for birth center care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Scope of care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Licensing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Standards and accreditation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Medicolegal liability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      EVIDENCE SUPPORTING THE BIRTH CENTER MODEL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H137349612\">",
"      The National Birth Center Study",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - The National Birth Center Study, 1985-1987",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6019821\">",
"      - The National Birth Center Study II, 2007 to 2010",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2963016\">",
"      - Limitations of these studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14173429\">",
"      Studies comparing the costs of maternity care in birth centers versus hospital",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4456\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4456|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?19/58/20392\" title=\"form 1A\">",
"      Birth center consent 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?27/30/28137\" title=\"form 1B\">",
"      Birth center consent 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?39/56/40837\" title=\"form 1C\">",
"      Birth center consent 3",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/20/22855?source=related_link\">",
"      Continuous intrapartum support",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/7/23674?source=related_link\">",
"      Intrapartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/44/38601?source=related_link\">",
"      Nonpharmacological approaches to management of labor pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/53/20312?source=related_link\">",
"      Planned home birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10311?source=related_link\">",
"      Preparation for labor and childbirth",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_29_25049="Clinical features, diagnosis, and treatment of radiation proctitis";
var content_f24_29_25049=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, diagnosis, and treatment of radiation proctitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/29/25049/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/29/25049/contributors\">",
"     Timothy T Nostrant, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/29/25049/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/29/25049/contributors\">",
"     Lawrence S Friedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/29/25049/contributors\">",
"     Christopher G Willett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/29/25049/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/29/25049/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/29/25049/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation injury to the lower intestine may be encountered following treatment of cancers of the rectum, cervix, uterus, prostate, urinary bladder, and testes. Thus, the rectum and sigmoid colon are most often affected.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of chronic radiation proctitis will be reviewed here. The issues related to radiation enteritis (ie, involving the small intestine) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13975?source=see_link\">",
"     \"Diagnosis and management of chronic radiation enteritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=see_link\">",
"     \"Gastrointestinal toxicity of radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of injury caused by radiation exposure can be divided into two categories: acute and chronic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11872851\">",
"    <span class=\"h2\">",
"     Acute radiation proctitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute radiation proctitis occurs during and within six weeks of radiation therapy.",
"   </p>",
"   <p>",
"    Symptoms include diarrhea and rectal urgency or tenesmus, and, uncommonly, bleeding. Acute radiation injury is caused by direct mucosal damage from radiation exposure and usually resolves after radiation is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/1,2\">",
"     1,2",
"    </a>",
"    ], although some patients report persistent symptoms for at least one year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/3\">",
"     3",
"    </a>",
"    ]. Raised levels of fecal calprotectin and fecal lactoferrin are seen in all patients with acute proctitis and may be predictive of progression to chronic proctitis if elevated four weeks after completion of radiation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11872757\">",
"    <span class=\"h2\">",
"     Chronic radiation proctitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic radiation proctitis has a more delayed onset. The first symptoms often occur 9 to 14 months following radiation exposure but can occur any time post-irradiation up to 30 years after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/1,6,7\">",
"     1,6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late radiation injury is due to progressive epithelial atrophy and fibrosis associated with obliterative endarteritis and chronic mucosal ischemia. The end result is a chronically ischemic intestinal segment that is prone to stricture formation and bleeding. The term \"proctitis\" is somewhat misleading since it inaccurately implies a chronic inflammatory condition. As a result, authorities prefer to refer to it as a chronic radiation \"proctopathy\". However, because radiation proctitis is still used commonly, it will be used in this topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=see_link\">",
"     \"Biology and clinical features of radiation injury in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11872693\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms include diarrhea, obstructed defecation (in patients who have developed strictures), bleeding, rectal pain or urgency, and less commonly fecal incontinence.",
"   </p>",
"   <p>",
"    Concomitant injury to the genitourinary tract or small bowel may lead to fistulas, small bowel obstruction, small bowel bacterial overgrowth, urethral stenosis, and cystitis. These symptoms may be associated with a significant decrease in health-related quality of life in up to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/8-11\">",
"     8-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiation exposure also increases the risk of secondary malignancy including colorectal cancer, which usually occurs more than 10 years after exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=see_link&amp;anchor=H14#H14\">",
"     \"Colorectal cancer: Epidemiology, risk factors, and protective factors\", section on 'Other risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic radiation proctitis or sigmoiditis should be suspected in patients who have the above clinical features developing nine months or more after pelvic radiation exposure. In most patients, the diagnosis can be confirmed during colonoscopy or sigmoidoscopy. Mucosal features consistent with radiation injury include pallor with friability, and telangiectasias [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/15\">",
"     15",
"    </a>",
"    ], which can be multiple, large, and serpiginous; these changes tend to be continuous without skip lesions but can be patchy in intensity.",
"   </p>",
"   <p>",
"    Although mucosal biopsies are not diagnostic, they can help to exclude other causes of proctitis such as infection or inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=see_link\">",
"     \"Endoscopic diagnosis of inflammatory bowel disease\"",
"    </a>",
"    .) A histologic classification system has been proposed but its role has not yet been defined [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a concern related to fistula formation from obtaining rectal biopsies over the prostate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/18\">",
"     18",
"    </a>",
"    ]. It is likely that patients in whom this occurred had severe necrosis and hence the contribution of the biopsy to the fistula formation is unclear. Rectal biopsies should be performed judiciously depending upon the clinical indication as well as the dose and fractionation of previous pelvic radiation therapy. If required, they should be directed at the posterior and lateral walls to avoid the irradiated areas.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     Barium",
"    </a>",
"    studies are helpful in patients who have obstructive symptoms and are preferred in those suspected of having fistulas. In such patients, a computed tomography (CT) scan may also be necessary to exclude recurrent malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21980573\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary approach to the prevention of radiation proctitis is the use of contemporary conformal radiation therapy techniques (eg, intensity modulated radiation therapy, intensity guided radiation therapy) that minimize the dose of radiation to the rectum while maximizing dose to the tumor. Attempts to use adjunctive medical therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     amifostine",
"    </a>",
"    ) to prevent the development of radiation proctitis have had only a minimal effect and are not widely used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H2#H2\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'External beam RT techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no large controlled trials evaluating treatment of radiation proctitis or proctosigmoiditis. Thus, experience is derived mostly from case reports and small clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1467660411\">",
"    <span class=\"h2\">",
"     Acute radiation proctitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Butyrate enemas may accelerate healing in acute radiation proctitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Other therapies have not been consistently found to be of benefit in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1467660418\">",
"    <span class=\"h2\">",
"     Chronic radiation proctitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review focusing on six trials that included a control group [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/21-26\">",
"     21-26",
"    </a>",
"    ] found that there were insufficient data to make firm conclusions regarding any therapy, although some treatments (including rectal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    combined with topical antiinflammatory treatment, and heater probe application) appeared promising [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment should be based upon the pattern and severity of symptoms (",
"    <a class=\"graphic graphic_table graphicRef53812 \" href=\"UTD.htm?4/46/4844\">",
"     table 1",
"    </a>",
"    ). No specific therapy is required in patients whose symptoms are mild, such as those with small amounts of rectal bleeding in whom symptoms may improve spontaneously. In one series, for example, bleeding subsided spontaneously within six months in 35 percent of patients who initially had only mild rectal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, patients whose symptoms are more severe may not have such a favorable prognosis. Several approaches have been tried in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Stool softeners",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stool softeners may be helpful for mild obstructive symptoms related to strictures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balloon or Savary-Gilliard dilation can be effective in patients with obstructive symptoms from strictures who do not respond to stool softeners provided that the strictured segment is short [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/28\">",
"     28",
"    </a>",
"    ]. The risk of perforation is increased in patients with long or angulated strictures. Such patients may require surgery if obstruction is significant clinically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sulfasalazine and aminosalicylates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    and aminosalicylates in idiopathic ulcerative colitis prompted their use in radiation proctitis given as oral or enema preparations. Although some reports and anecdotal experience have suggested that this approach may be successful [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/29\">",
"     29",
"    </a>",
"    ], the results in other series have been disappointing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The addition of rectal",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    enemas to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    improved symptoms in a controlled trial in which combined therapy was compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    enemas (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Sucralfate'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/21\">",
"     21",
"    </a>",
"    ]. The efficacy of corticosteroid enemas alone has been poorly studied. However, clinical experience with this approach has been disappointing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sucralfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have suggested that topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    may improve symptoms of radiation proctitis or proctosigmoiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/21,31-34\">",
"     21,31-34",
"    </a>",
"    ]. The rationale for its use is based upon its favorable effects on epithelial microvascular injury [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective, double-blind trial, 37 patients with proctosigmoiditis were randomly assigned to a four-week course of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (3.0",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    enemas (20 mg twice daily) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    enemas (2.0 g twice daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/31\">",
"     31",
"    </a>",
"    ]. Clinical improvement was noted in both groups at the end of the study. However, the response was better for sucralfate enemas, which were also better tolerated.",
"   </p>",
"   <p>",
"    Another report from the same authors included 26 patients with moderate to severe radiation proctosigmoiditis who were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     sucralfate",
"    </a>",
"    enemas (20 mL of a 10 percent suspension twice daily) until bleeding stopped or failure of therapy was acknowledged [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/31\">",
"     31",
"    </a>",
"    ]. The response was considered good when the severity of bleeding improved by at least two grades, which was defined by the number of episodes of bleeding per week. A good response was observed in 77 percent of patients by four weeks, and 92 percent by 16 weeks. These results await confirmation in larger controlled trials.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"     Sucralfate",
"    </a>",
"    has also been evaluated for prophylaxis against acute radiation injury. However, placebo-controlled phase III trials have detected no benefit from either topical or oral sucralfate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hormonal therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hormonal therapy with estrogen (with or without progesterone) has been used to control obscure gastrointestinal bleeding in patients with Osler-Weber-Rendu syndrome, von Willebrand's disease, end-stage renal disease, and angiodysplasia alone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=see_link\">",
"     \"Angiodysplasia of the gastrointestinal tract\"",
"    </a>",
"    .) Although experience with treating radiation proctosigmoiditis is limited, at least one case series suggested a possible benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/39\">",
"     39",
"    </a>",
"    ]. However, side effects of hormonal therapy observed during treatment of patients with angiodysplasias are common, and the efficacy of therapy has not been uniform.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The theoretical benefit of hyperbaric oxygen therapy (HBO) may be via inhibition of bacterial growth [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/40\">",
"     40",
"    </a>",
"    ], preservation of marginally perfused tissue, and inhibition of toxin production [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/41\">",
"     41",
"    </a>",
"    ]. HBO has been used for treatment of refractory foot ulcers in diabetes and in other conditions.",
"   </p>",
"   <p>",
"    A potential role for hyperbaric oxygen in patients with chronic radiation proctitis has been described in several observational studies and in at least one randomized controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]. The controlled trial included 120 patients with refractory radiation proctitis who were randomly assigned to hyperbaric oxygen or to a sham procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/43\">",
"     43",
"    </a>",
"    ]. The clinical response rate was significantly higher in the intervention group (89 versus 63 percent). In addition, symptom improvement was accompanied by a decreased requirement for other treatments. The study was potentially limited by a large number of dropouts after allocation and unclear blinding.",
"   </p>",
"   <p>",
"    The equipment needed for hyperbaric oxygen treatment is expensive and not widely available. Thus, at the present time, it is not a practical means of treating chronic radiation proctitis outside of centers specializing in this approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Short-chain fatty acid enemas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-chain fatty acids (SCFAs) are the preferred luminal nutrients for colonocytes. SCFA enemas have been effective for treatment of diversion colitis, prompting their study in radiation proctitis. Although case reports suggested a possible benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/47\">",
"     47",
"    </a>",
"    ], no significant improvement in symptoms was found in a placebo-controlled study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9414?source=see_link\">",
"     \"Diversion colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pentosan polysulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36467?source=see_link\">",
"     Pentosan polysulfate",
"    </a>",
"    is a low-molecular weight heparin-like compound with anticoagulant and fibrinolytic effects, which has been approved for the treatment of interstitial cystitis. Although a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    pilot study suggested benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/48\">",
"     48",
"    </a>",
"    ], a phase III trial that randomly assigned 180 patients to placebo or one of two doses of pentosan found no improvement in radiation-induced symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Metronidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    was evaluated in study that included 60 patients with rectal bleeding and diarrhea who were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    enemas with or without metronidazole (400 mg orally three times daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/26\">",
"     26",
"    </a>",
"    ]. The incidence of rectal bleeding and mucosal ulcers was lower in the metronidazole groups at four weeks, three months, and 12 months. Diarrhea and edema were also reduced in the metronidazole group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Formaldehyde",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formaldehyde induces coagulative tissue necrosis on contact, providing a rationale for its use in patients with radiation proctitis who have significant bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/50-58\">",
"     50-58",
"    </a>",
"    ]. Several series (using variations in technique) have described improvement or cessation of bleeding. The procedure has generally been well tolerated, although serious complications including the development of fistulas requiring colostomy and bowel necrosis requiring resection have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/53\">",
"     53",
"    </a>",
"    ]. Direct contact of the formalin with the anoderm can be extremely irritating to the skin and should be avoided. Endoscopic flushing out of residual formaldehyde with saline may be prudent. The following illustrate the range of findings.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one report, 29 patients with severe bleeding from radiation proctitis that had been refractory to other types of therapy were treated by the application of 4 percent formalin-soaked gauze to the affected areas in the rectum via a rigid sigmoidoscope for as long as was required to achieve hemostasis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/50\">",
"       50",
"      </a>",
"      ]. One month after therapy, 17 patients had complete cessation of bleeding and 11 only had minor bleeding. After a median of 12 months, bleeding had stopped completely in 22 of the 29 patients (76 percent). Treatment was generally well-tolerated. One patient had worsening of a radiation-induced stricture that required dilation.",
"     </li>",
"     <li>",
"      A later series included 33 patients, 23 of whom required one formalin application while 10 required a second application because of persistent bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/54\">",
"       54",
"      </a>",
"      ]. Treatment was considered to be effective in 23 patients (70 percent); 13 had complete cessation of bleeding while 10 had only minor bleeding. Six anal or rectal strictures developed after treatment and fecal incontinence worsened in five patients and developed in an additional four patients. The authors concluded that formalin application was effective but morbidity was not negligible. Many of the patients who developed complications had been treated for anal cancer (four of the six patients who developed a stricture and in all five of the patients who developed worsening incontinence) possibly explaining the increased morbidity compared with other series.",
"     </li>",
"     <li>",
"      In a variation on the technique, 20 mL of a 5 percent formalin solution were instilled into the rectum during flexible sigmoidoscopy without sedation [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/59\">",
"       59",
"      </a>",
"      ]. A single session was effective in controlling bleeding in 13 of 20 patients (65 percent) while four responded to a second treatment. Average follow-up was 23 months. There were no serious complications but the sample size was small.",
"     </li>",
"     <li>",
"      Another series described 100 patients who were treated by direct application of a 10 percent buffered formalin solution to the affected area using a 16-inch cotton tip applicator [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/58\">",
"       58",
"      </a>",
"      ]. Treatment was applied through a proctoscope in the office. Overall, 93 percent of patients had cessation of bleeding after an average of 3.5 applications at two to four week intervals. Three patients complained of anal pain and one of dizziness after the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antioxidants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible role of oxidative injury in chronic radiation proctitis provided the rationale for a study of antioxidants. A small uncontrolled study involving 10 patients suggested that treatment with vitamin E (400 international units three times daily) and vitamin C (500 mg three times daily) was associated with improvement in diarrhea and urgency [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/60\">",
"     60",
"    </a>",
"    ]. The high dropout rate in the study (only one-half of the originally treated patients were available for follow-up), the relatively subjective endpoints used, and the absence of a control group make it difficult to draw any conclusions. Controlled trials are needed before antioxidant therapy can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vitamin A",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential role for oral retinol palmitate was suggested in a pilot, placebo-controlled trial involving 18 patients with radiation proctitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/61\">",
"     61",
"    </a>",
"    ]. Response (defined as a reduction in two or more symptoms by at least two points on a validated scale) was observed significantly more often in the group randomized to retinol palmitate. In addition, five placebo nonresponders subsequently responded to active treatment during crossover. The authors hypothesized that the benefit might be due to improved wound healing. Further studies are needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Endoscopic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of endoscopic methods have been used to treat radiation colitis. Although most are best suited to treat bleeding, they may have additional benefits for other symptoms.",
"   </p>",
"   <p>",
"    Changes in prostate radiation protocols in recent years, including combination implant and external beam irradiation with high radiation exposure, have been associated with rectourethral fistulas in the first six months to two years likely secondary to radiation-induced prostate necrosis and early and aggressive endoscopic treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, all forms of treatment and biopsies should be coordinated with the radiation urologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Argon plasma coagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Argon plasma coagulation (APC) uses high frequency energy transmitted to tissue by ionized gas. It has been used to treat a wide spectrum of bleeding lesions in the gastrointestinal tract. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=see_link\">",
"     \"Argon plasma coagulation in the management of gastrointestinal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of APC has been suggested in several case series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/62-66\">",
"     62-66",
"    </a>",
"    ]. An illustrative report included 28 patients with persistent bleeding despite medical therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/63\">",
"     63",
"    </a>",
"    ]. The majority of patients had improvement in bleeding and anemia after a median of 2.9 sessions (range one to eight). All visible lesions were targeted at each session and follow-up procedures were scheduled in four-week intervals to allow the tissue to heal (",
"    <a class=\"graphic graphic_picture graphicRef64264 \" href=\"UTD.htm?33/51/34608\">",
"     picture 1",
"    </a>",
"    ). The mean hemoglobin rose by 1.2",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    and by 1.9",
"    <span class=\"nowrap\">",
"     gm/dL",
"    </span>",
"    among individuals presenting with anemia. Some patients experienced post-procedure rectal pain and cramps, but no major complications occurred. Other reports have demonstrated that APC may control bleeding even after unsuccessful treatment using other methods [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Special care is required to avoid spraying too close to the dentate line. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=see_link\">",
"     \"Argon plasma coagulation in the management of gastrointestinal hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     Mesalamine",
"    </a>",
"    suppositories",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    corticosteroid enemas are often used to help treat rectal ulceration associated with APC. Treatment-related ulcers (present in more than one-half of patients) should be avoided during subsequent sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/67\">",
"     67",
"    </a>",
"    ]. A complete bowel lavage maximizes safety before each procedure. A potential complication if this is not done is bowel explosion with perforation, presumably due to the accumulation of combustible colonic gas [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The argon and Nd:YAG laser have been used to coagulate bleeding ectatic vessels throughout the gastrointestinal tract [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/69-73\">",
"     69-73",
"    </a>",
"    ]. These devices are not widely available.",
"   </p>",
"   <p>",
"    The potential benefit of this approach was illustrated in a report in which the Nd:YAG laser was used in nine patients, of whom six required periodic blood transfusion: bleeding was reduced to only occasional spotting in six patients, with only one continuing to require periodic blood transfusions during follow-up of 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a small pilot study, 7 out of 10 patients with radiation proctitis responded to cryoablation spray ablation with a decrease in rectal telangiectasia density and improvement in radiation proctitis symptom severity. One complication of cecal perforation due to gas overdistention was seen. Controlled trials are needed to establish the safety and efficacy of cryoablation for radiation proctitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Bipolar and heater probe",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bipolar electrocoagulation (BiCap) and the heater probe have several advantages compared to laser therapy. They cause less tissue injury, permit tangential application of cautery, and the equipment needed is widely available and relatively inexpensive.",
"   </p>",
"   <p>",
"    These techniques were evaluated in a study involving 21 patients with chronic recurrent hematochezia and anemia due to radiation-induced injury who were followed for 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients were treated with either BiCap or heater probe therapy as needed. Severe bleeding diminished significantly after these treatments compared to the previous twelve months of medical therapy (75 versus 33 percent and 67 versus 11 percent, respectively). The decreased rate of bleeding was accompanied by an improvement in the hematocrit in both groups. There were no major complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery should be reserved for patients who have intractable symptoms such as strictures, pain, or bleeding, since it may be technically demanding due to adhesions and other radiation damage in the pelvis. In one review of 48 patients who had been referred for severe refractory radiotherapy complications that had failed initial treatment, surgery was generally required for patients with a fistula and permanent diversion and was more likely in patients with severe radiation enteritis and distal colonic strictures [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/75\">",
"     75",
"    </a>",
"    ]. A concern with surgery is that anastomoses involving radiated tissue can break down [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/76\">",
"     76",
"    </a>",
"    ]. Total rectal resection may be the only option in some patients. In this setting, construction of an ileocecal reservoir has been associated with a good functional outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute radiation proctitis occurs during and within six weeks of radiation therapy.",
"     </li>",
"     <li>",
"      Chronic radiation proctitis should be suspected in patients who have compatible clinical features developing nine months or more after pelvic radiation exposure. Symptoms include diarrhea, obstructed defecation (in patients who have developed strictures), bleeding, rectal pain or urgency, and less commonly fecal incontinence. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mucosal features consistent with radiation injury include pallor with friability, and telangiectasias, which can be multiple, large, and serpiginous; these changes tend to be continuous without skip areas but can be patchy in intensity. Although mucosal biopsies are not diagnostic, they can help to exclude other causes of proctitis such as infection or inflammatory bowel disease. Because of a concern related to fistula formation, rectal biopsies should be performed judiciously depending upon the clinical indication as well as the dose and fractionation of previous pelvic radiation therapy. If required, they should be directed at the posterior and lateral walls to avoid the irradiated areas. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In acute radiation proctitis, butyrate enemas may accelerate healing [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25049/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. Other therapies have not been consistently found to be of benefit in this setting.",
"     </li>",
"     <li>",
"      In patients with chronic radiation proctitis, selection among the treatment options should be based upon the type of symptoms and their severity, and experience within the treatment center. Specific therapy may not be necessary in those who have only mild symptoms, such as occasional hematochezia or mild tenesmus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Obstructive symptoms",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest stool softeners in patients who have mild obstructive symptoms related to strictures (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In those with narrower strictures, we suggest balloon or Savary-Gilliard dilation provided that the strictured segment is short (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The risk of perforation is increased in patients with long or angulated strictures. Such patients may require surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild bleeding may not require treatment since bleeding may remit spontaneously within six months in up to one-third of more of these patients. Several options are available in patients with persistent or more severe bleeding. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because medical therapy is safe and may be effective, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       sucralfate",
"      </a>",
"      enema therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Although experience is limited, sucralfate enemas (20 mL of a 10 percent sucralfate suspension in water twice daily) were more effective than oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      even when combined with corticosteroid enemas. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Sucralfate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For nonresponders, we suggest a trial of the endoscopic methods (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Most clinicians dealing with radiation proctitis prefer APC because of ease of use and predictable response. Formalin application may be an acceptable alternative, which may also reduce the need for recurrent procedures that are often required with the endoscopic methods. However, the possibility of serious complications requiring bowel resection or colostomy should be considered when weighing alternatives. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Endoscopic therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The timing of these approaches should be coordinated with a radiation",
"      <span class=\"nowrap\">",
"       oncologist/urologist.",
"      </span>",
"      Aggressive endoscopic therapy in the setting of prostate necrosis may be associated with an increased risk of fistula formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Tenesmus and rectal pain",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with tenesmus or rectal pain we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/29/29141?source=see_link\">",
"       sucralfate",
"      </a>",
"      or corticosteroid enemas (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In comparison, 5-ASA enemas do not appear to be helpful in this setting. While oral 5-ASA or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      continue to be used in clinical practice, evidence supporting their benefit in this setting is limited. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Sulfasalazine and aminosalicylates'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Sucralfate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/1\">",
"      Schultheiss TE, Lee WR, Hunt MA, et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/2\">",
"      Henson C. Chronic radiation proctitis: issues surrounding delayed bowel dysfunction post-pelvic radiotherapy and an update on medical treatment. Therap Adv Gastroenterol 2010; 3:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/3\">",
"      Haddock MG, Sloan JA, Bollinger JW, et al. Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial. J Clin Oncol 2007; 25:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/4\">",
"      Hille A, Rave-Fr&auml;nk M, Christiansen H, et al. Faecal calprotectin and lactoferrin values during irradiation of prostate cancer correlate with chronic radiation proctitis: results of a prospective study. Scand J Gastroenterol 2009; 44:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/5\">",
"      Hille A, Schmidt-Giese E, Hermann RM, et al. A prospective study of faecal calprotectin and lactoferrin in the monitoring of acute radiation proctitis in prostate cancer treatment. Scand J Gastroenterol 2008; 43:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/6\">",
"      Gilinsky NH, Burns DG, Barbezat GO, et al. The natural history of radiation-induced proctosigmoiditis: an analysis of 88 patients. Q J Med 1983; 52:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/7\">",
"      Lucarotti ME, Mountford RA, Bartolo DC. Surgical management of intestinal radiation injury. Dis Colon Rectum 1991; 34:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/8\">",
"      Turini M, Redaelli A, Gramegna P, Radice D. Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics 2003; 21:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/9\">",
"      Bloch S, Love A, Macvean M, et al. Psychological adjustment of men with prostate cancer: a review of the literature. Biopsychosoc Med 2007; 1:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/10\">",
"      Henderson A, Andreyev HJ, Stephens R, Dearnaley D. Patient and physician reporting of symptoms and health-related quality of life in trials of treatment for early prostate cancer: considerations for future studies. Clin Oncol (R Coll Radiol) 2006; 18:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/11\">",
"      Lev EL, Eller LS, Gejerman G, et al. Quality of life of men treated with brachytherapies for prostate cancer. Health Qual Life Outcomes 2004; 2:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/12\">",
"      Liauw SL, Sylvester JE, Morris CG, et al. Second malignancies after prostate brachytherapy: incidence of bladder and colorectal cancers in patients with 15 years of potential follow-up. Int J Radiat Oncol Biol Phys 2006; 66:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/13\">",
"      Moon K, Stukenborg GJ, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer. Cancer 2006; 107:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/14\">",
"      Baxter NN, Tepper JE, Durham SB, et al. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology 2005; 128:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/15\">",
"      O'Brien PC, Hamilton CS, Denham JW, et al. Spontaneous improvement in late rectal mucosal changes after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004; 58:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/16\">",
"      Shepherd NA. Pathological mimics of chronic inflammatory bowel disease. J Clin Pathol 1991; 44:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/17\">",
"      Goldner G, Tomicek B, Becker G, et al. Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC/RTOG score for late rectal toxicity: results of a prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys 2007; 67:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/18\">",
"      Chrouser KL, Leibovich BC, Sweat SD, et al. Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol 2005; 173:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/19\">",
"      Vernia P, Fracasso PL, Casale V, et al. Topical butyrate for acute radiation proctitis: randomised, crossover trial. Lancet 2000; 356:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/20\">",
"      Hille A, Herrmann MK, Kertesz T, et al. Sodium butyrate enemas in the treatment of acute radiation-induced proctitis in patients with prostate cancer and the impact on late proctitis. A prospective evaluation. Strahlenther Onkol 2008; 184:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/21\">",
"      Kochhar R, Patel F, Dhar A, et al. Radiation-induced proctosigmoiditis. Prospective, randomized, double-blind controlled trial of oral sulfasalazine plus rectal steroids versus rectal sucralfate. Dig Dis Sci 1991; 36:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/22\">",
"      Talley NA, Chen F, King D, et al. Short-chain fatty acids in the treatment of radiation proctitis: a randomized, double-blind, placebo-controlled, cross-over pilot trial. Dis Colon Rectum 1997; 40:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/23\">",
"      Jensen DM, Machicado GA, Cheng S, et al. A randomized prospective study of endoscopic bipolar electrocoagulation and heater probe treatment of chronic rectal bleeding from radiation telangiectasia. Gastrointest Endosc 1997; 45:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/24\">",
"      Rougier P, Zimmerman P, Pignon J, et al. Rectites radiques: Efficate comparee de deux types de corticoides adminstre localement. Med Chir Dig 1992; 21:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/25\">",
"      Pinto A, Fidalgo P, Cravo M, et al. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: randomized, double-blind, controlled trial. Dis Colon Rectum 1999; 42:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/26\">",
"      Cavci�� J, Turci�� J, Martinac P, et al. Metronidazole in the treatment of chronic radiation proctitis: clinical trial. Croat Med J 2000; 41:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/27\">",
"      Denton A, Forbes A, Andreyev J, Maher EJ. Non surgical interventions for late radiation proctitis in patients who have received radical radiotherapy to the pelvis. Cochrane Database Syst Rev 2002; :CD003455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/28\">",
"      Triadafilopoulos G, Sarkisian M. Dilatation of radiation-induced sigmoid stricture using sequential Savary-Guilliard dilators. A combined radiologic-endoscopic approach. Dis Colon Rectum 1990; 33:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/29\">",
"      Goldstein F, Khoury J, Thornton JJ. Treatment of chronic radiation enteritis and colitis with salicylazosulfapyridine and systemic corticosteroids. A pilot study. Am J Gastroenterol 1976; 65:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/30\">",
"      Baum CA, Biddle WL, Miner PB Jr. Failure of 5-aminosalicylic acid enemas to improve chronic radiation proctitis. Dig Dis Sci 1989; 34:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/31\">",
"      Kochhar R, Sriram PV, Sharma SC, et al. Natural history of late radiation proctosigmoiditis treated with topical sucralfate suspension. Dig Dis Sci 1999; 44:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/32\">",
"      Chun M, Kang S, Kil HJ, et al. Rectal bleeding and its management after irradiation for uterine cervical cancer. Int J Radiat Oncol Biol Phys 2004; 58:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/33\">",
"      Sasai T, Hiraishi H, Suzuki Y, et al. Treatment of chronic post-radiation proctitis with oral administration of sucralfate. Am J Gastroenterol 1998; 93:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/34\">",
"      Stockdale AD, Biswas A. Long-term control of radiation proctitis following treatment with sucralfate enemas. Br J Surg 1997; 84:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/35\">",
"      Sandor Z, Nagata M, Kusstatscher S, Szabo S. Stimulation of mucosal glutathione and angiogenesis: new mechanisms of gastroprotection and ulcer healing by sucralfate. Scand J Gastroenterol Suppl 1995; 210:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/36\">",
"      Konturek SJ, Brzozowski T, Majka J, et al. Fibroblast growth factor in gastroprotection and ulcer healing: interaction with sucralfate. Gut 1993; 34:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/37\">",
"      O'Brien PC, Franklin CI, Poulsen MG, et al. Acute symptoms, not rectally administered sucralfate, predict for late radiation proctitis: longer term follow-up of a phase III trial--Trans-Tasman Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2002; 54:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/38\">",
"      Kneebone A, Mameghan H, Bolin T, et al. Effect of oral sucralfate on late rectal injury associated with radiotherapy for prostate cancer: A double-blind, randomized trial. Int J Radiat Oncol Biol Phys 2004; 60:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/39\">",
"      Wurzer H, Schafhalter-Zoppoth I, Brandst&auml;tter G, Stranzl H. Hormonal therapy in chronic radiation colitis. Am J Gastroenterol 1998; 93:2536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/40\">",
"      Hill GB, Osterhout S. Experimental effects of hyperbaric oxgen on selected clostridial species. I. In-vitro studies. J Infect Dis 1972; 125:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/41\">",
"      . INHIBITION OF TOXIN PRODUCTION IN CLOSTRIDIUM PERFRINGENS IN VITRO BY HYPERBARIC OXYGEN. Antonie Van Leeuwenhoek 1965; 31:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/42\">",
"      Dall'Era MA, Hampson NB, Hsi RA, et al. Hyperbaric oxygen therapy for radiation induced proctopathy in men treated for prostate cancer. J Urol 2006; 176:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/43\">",
"      Clarke RE, Tenorio LM, Hussey JR, et al. Hyperbaric oxygen treatment of chronic refractory radiation proctitis: a randomized and controlled double-blind crossover trial with long-term follow-up. Int J Radiat Oncol Biol Phys 2008; 72:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/44\">",
"      Craighead P, Shea-Budgell MA, Nation J, et al. Hyperbaric oxygen therapy for late radiation tissue injury in gynecologic malignancies. Curr Oncol 2011; 18:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/45\">",
"      Bennett MH, Feldmeier J, Hampson N, et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev 2005; :CD005005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/46\">",
"      Oliai C, Fisher B, Jani A, et al. Hyperbaric oxygen therapy for radiation-induced cystitis and proctitis. Int J Radiat Oncol Biol Phys 2012; 84:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/47\">",
"      al-Sabbagh R, Sinicrope FA, Sellin JH, et al. Evaluation of short-chain fatty acid enemas: treatment of radiation proctitis. Am J Gastroenterol 1996; 91:1814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/48\">",
"      Grigsby PW, Pilepich MV, Parsons CL. Preliminary results of a phase I/II study of sodium pentosanpolysulfate in the treatment of chronic radiation-induced proctitis. Am J Clin Oncol 1990; 13:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/49\">",
"      Pilepich MV, Paulus R, St Clair W, et al. Phase III study of pentosanpolysulfate (PPS) in treatment of gastrointestinal tract sequelae of radiotherapy. Am J Clin Oncol 2006; 29:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/50\">",
"      Mathai V, Seow-Choen F. Endoluminal formalin therapy for haemorrhagic radiation proctitis. Br J Surg 1995; 82:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/51\">",
"      Seow-Choen F, Goh HS, Eu KW, et al. A simple and effective treatment for hemorrhagic radiation proctitis using formalin. Dis Colon Rectum 1993; 36:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/52\">",
"      Biswal BM, Lal P, Rath GK, et al. Intrarectal formalin application, an effective treatment for grade III haemorrhagic radiation proctitis. Radiother Oncol 1995; 35:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/53\">",
"      Luna-P&eacute;rez P, Rodr&iacute;guez-Ram&iacute;rez SE. Formalin instillation for refractory radiation-induced hemorrhagic proctitis. J Surg Oncol 2002; 80:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/54\">",
"      de Parades V, Etienney I, Bauer P, et al. Formalin application in the treatment of chronic radiation-induced hemorrhagic proctitis--an effective but not risk-free procedure: a prospective study of 33 patients. Dis Colon Rectum 2005; 48:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/55\">",
"      Counter SF, Froese DP, Hart MJ. Prospective evaluation of formalin therapy for radiation proctitis. Am J Surg 1999; 177:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/56\">",
"      Isenberg GA, Goldstein SD, Resnik AM. Formalin therapy for radiation proctitis. JAMA 1994; 272:1822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/57\">",
"      Parikh S, Hughes C, Salvati EP, et al. Treatment of hemorrhagic radiation proctitis with 4 percent formalin. Dis Colon Rectum 2003; 46:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/58\">",
"      Haas EM, Bailey HR, Farragher I. Application of 10 percent formalin for the treatment of radiation-induced hemorrhagic proctitis. Dis Colon Rectum 2007; 50:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/59\">",
"      Cullen SN, Frenz M, Mee A. Treatment of haemorrhagic radiation-induced proctopathy using small volume topical formalin instillation. Aliment Pharmacol Ther 2006; 23:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/60\">",
"      Kennedy M, Bruninga K, Mutlu EA, et al. Successful and sustained treatment of chronic radiation proctitis with antioxidant vitamins E and C. Am J Gastroenterol 2001; 96:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/61\">",
"      Ehrenpreis ED, Jani A, Levitsky J, et al. A prospective, randomized, double-blind, placebo-controlled trial of retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy. Dis Colon Rectum 2005; 48:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/62\">",
"      Fantin AC, Binek J, Suter WR, Meyenberger C. Argon beam coagulation for treatment of symptomatic radiation-induced proctitis. Gastrointest Endosc 1999; 49:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/63\">",
"      Silva RA, Correia AJ, Dias LM, et al. Argon plasma coagulation therapy for hemorrhagic radiation proctosigmoiditis. Gastrointest Endosc 1999; 50:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/64\">",
"      Tjandra JJ, Sengupta S. Argon plasma coagulation is an effective treatment for refractory hemorrhagic radiation proctitis. Dis Colon Rectum 2001; 44:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/65\">",
"      Ta&iuml;eb S, Rolachon A, Cenni JC, et al. Effective use of argon plasma coagulation in the treatment of severe radiation proctitis. Dis Colon Rectum 2001; 44:1766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/66\">",
"      Karamanolis G, Triantafyllou K, Tsiamoulos Z, et al. Argon plasma coagulation has a long-lasting therapeutic effect in patients with chronic radiation proctitis. Endoscopy 2009; 41:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/67\">",
"      Ravizza D, Fiori G, Trovato C, Crosta C. Frequency and outcomes of rectal ulcers during argon plasma coagulation for chronic radiation-induced proctopathy. Gastrointest Endosc 2003; 57:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/68\">",
"      Ben Soussan E, Mathieu N, Roque I, Antonietti M. Bowel explosion with colonic perforation during argon plasma coagulation for hemorrhagic radiation-induced proctitis. Gastrointest Endosc 2003; 57:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/69\">",
"      Berken CA. Nd:YAG laser therapy for gastrointestinal bleeding due to radiation colitis. Am J Gastroenterol 1985; 80:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/70\">",
"      Barbatzas C, Spencer GM, Thorpe SM, et al. Nd:YAG laser treatment for bleeding from radiation proctitis. Endoscopy 1996; 28:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/71\">",
"      Viggiano TR, Zighelboim J, Ahlquist DA, et al. Endoscopic Nd:YAG laser coagulation of bleeding from radiation proctopathy. Gastrointest Endosc 1993; 39:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/72\">",
"      Taylor JG, DiSario JA, Buchi KN. Argon laser therapy for hemorrhagic radiation proctitis: long-term results. Gastrointest Endosc 1993; 39:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/73\">",
"      Buchi KN, Dixon JA. Argon laser treatment of hemorrhagic radiation proctitis. Gastrointest Endosc 1987; 33:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/74\">",
"      Hou JK, Abudayyeh S, Shaib Y. Treatment of chronic radiation proctitis with cryoablation. Gastrointest Endosc 2011; 73:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/75\">",
"      Turina M, Mulhall AM, Mahid SS, et al. Frequency and surgical management of chronic complications related to pelvic radiation. Arch Surg 2008; 143:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/76\">",
"      Marks G, Mohiudden M. The surgical management of the radiation-injured intestine. Surg Clin North Am 1983; 63:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25049/abstract/77\">",
"      von Fl&uuml;e MO, Degen LP, Beglinger C, Harder FH. The ileocecal reservoir for rectal replacement in complicated radiation proctitis. Am J Surg 1996; 172:335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7058 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-A7B94B43F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25049=[""].join("\n");
var outline_f24_29_25049=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11872851\">",
"      Acute radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11872757\">",
"      Chronic radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11872693\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21980573\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1467660411\">",
"      Acute radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1467660418\">",
"      Chronic radiation proctitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Stool softeners",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sulfasalazine and aminosalicylates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sucralfate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hormonal therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Short-chain fatty acid enemas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pentosan polysulfate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Metronidazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Formaldehyde",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antioxidants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vitamin A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Endoscopic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Argon plasma coagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Lasers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Bipolar and heater probe",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Obstructive symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Tenesmus and rectal pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/7058\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/7058|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/51/34608\" title=\"picture 1\">",
"      XRT proctitis APC Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/7058|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/46/4844\" title=\"table 1\">",
"      RTOG LENT criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=related_link\">",
"      Angiodysplasia of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34695?source=related_link\">",
"      Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4106?source=related_link\">",
"      Biology and clinical features of radiation injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/25/42394?source=related_link\">",
"      Colorectal cancer: Epidemiology, risk factors, and protective factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13975?source=related_link\">",
"      Diagnosis and management of chronic radiation enteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/12/9414?source=related_link\">",
"      Diversion colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/48/14089?source=related_link\">",
"      Endoscopic diagnosis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=related_link\">",
"      External beam radiation therapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20137?source=related_link\">",
"      Gastrointestinal toxicity of radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=related_link\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_29_25050="Course and management of chronic aortic regurgitation in adults";
var content_f24_29_25050=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Course and management of chronic aortic regurgitation in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/29/25050/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/29/25050/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/29/25050/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/29/25050/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/29/25050/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/29/25050/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/29/25050/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 31, 2007.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term prognosis of patients with chronic aortic regurgitation (AR), particularly the favorable outlook of those who are asymptomatic, is well documented. Chronic AR generally evolves in a slow and insidious manner with a very low morbidity during a long asymptomatic phase. Some patients with mild AR remain asymptomatic for decades and do not progress to requiring treatment. Others exhibit progression of the regurgitant lesion with the gradual development of severe AR, left ventricular (LV) systolic dysfunction, and eventually heart failure (",
"    <a class=\"graphic graphic_table graphicRef54569 \" href=\"UTD.htm?0/37/604\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Survival rates for symptomatic patients improved over a few decades from a mean survival of 6.4 years in 1956 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/1\">",
"     1",
"    </a>",
"    ], to a 70 percent six-year survival in the 1970s [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/2-4\">",
"     2-4",
"    </a>",
"    ], to a more than 80 percent five-year survival in 1982 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/5\">",
"     5",
"    </a>",
"    ]. These reports demonstrate that many, if not most patients have a protracted clinical course, despite evidence of severe AR and cardiac symptoms.",
"   </p>",
"   <p>",
"    The volume load that burdens the left ventricle in patients with chronic AR leads to a series of compensatory myocardial and circulatory adjustments that can be affected by pharmacologic therapy and reversed by valve replacement. Thus, the management of patients with this disorder requires an understanding of the natural history of the disease, the use of vasodilator therapy, and the timing of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the course and management of chronic AR. The pathophysiology and major clinical features of chronic AR and issues related to acute AR in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=see_link\">",
"     \"Acute aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS AND COURSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prognostic indicators",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with severe AR is determined largely by symptom status and by left ventricular size and function (",
"    <a class=\"graphic graphic_table graphicRef54569 \" href=\"UTD.htm?0/37/604\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The association of symptoms of heart failure with prognosis was illustrated by a report from the Mayo Clinic of 246 patients with severe or moderately severe AR who were managed conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/7\">",
"     7",
"    </a>",
"    ]. Those with New York Heart Association class III or IV heart failure had an annual mortality of 25 percent, while those with class II heart failure had an annual mortality of 6 percent.",
"   </p>",
"   <p>",
"    In addition to symptom status, prognosis in patients with AR is assessed by measurements of left ventricular (LV) size and function, usually by echocardiography (",
"    <a class=\"graphic graphic_table graphicRef75256 \" href=\"UTD.htm?6/52/6989\">",
"     table 2",
"    </a>",
"    ), as recommended by the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    valvular guidelines (with 2008 update) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\", section on 'Echocardiogram'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1082?source=see_link\">",
"     \"Echocardiographic evaluation of the aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluation of LV size and function is important because there is not a necessary correlation between these parameters and symptoms. In one report of 450 patients, for example, 28 percent of patients with a left ventricular ejection fraction (LVEF) below 35 percent were asymptomatic, a value not significantly different from the 37 percent of patients with an LVEF &ge;50 percent who were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Stages and course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from patients undergoing aortic valve replacement, in addition to clinical information, has been used to develop criteria for the definition of compensated and decompensated stages of chronic AR (",
"    <a class=\"graphic graphic_table graphicRef69635 \" href=\"UTD.htm?7/8/7308\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8,10-16\">",
"     8,10-16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An LV end-diastolic dimension less than 65 mm and an LVEF &gt;55 percent indicate a compensated stage.",
"     </li>",
"     <li>",
"      An LV end-systolic volume greater than 60",
"      <span class=\"nowrap\">",
"       mL/m2,",
"      </span>",
"      an LV end-systolic dimension greater than 50 mm, or an LVEF &lt;50 percent usually indicates serious depression of LV systolic function (decompensated stage).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The nature of the transition from a compensated to a decompensated stage is poorly understood and the definitions of these stages have not been validated in a prospective fashion. Thus, they should only be used as general guidelines in a decision analysis that includes all other clinical data and patient preferences. Nevertheless, this information has been useful in defining limits that are predictive of the future need for aortic valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For example, one report included serial studies in 77 asymptomatic patients with moderate to severe AR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/17\">",
"     17",
"    </a>",
"    ]. Most patients had LV enlargement but all had normal LV systolic function. During a mean follow-up duration of 49 months, there were no deaths but 12 underwent surgery because of the development of symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    LV dysfunction. By life table analysis, the percent of patients not requiring surgery was 90 percent at three years, 81 percent at five years, and 75 percent at seven years.",
"   </p>",
"   <p>",
"    Thus, asymptomatic patients with moderate to severe AR and a normal LVEF at baseline require aortic valve replacement at the rate of approximately",
"    <strong>",
"     4 percent per year",
"    </strong>",
"    . Similar findings were noted in a later study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis is not as good in asymptomatic patients with LV dysfunction. As many as two-thirds of such patients develop symptoms and require surgery within three years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One factor that may play a role in the progression of left ventricular dysfunction is vascular adaptation. In some patients, total arterial elastance, determined by measuring left ventricular pressure and left ventricular volumes during different loading conditions, decreases to maximize left ventricular work and to maintain performance [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/20\">",
"     20",
"    </a>",
"    ]. However, in other patients, elastance increases, enhancing afterload excess and leading to a reduction in left ventricular work and pump performance; this is most apparent in those with depressed left ventricular contractility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND MONITORING",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Identification of severe AR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of severe AR is primarily confirmed by echocardiography, since the physical findings are not reliable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\", section on 'Severity of AR'",
"    </a>",
"    .) Echocardiography can classify the severity of AR as mild, moderate, or severe (",
"    <a class=\"graphic graphic_table graphicRef53536 \" href=\"UTD.htm?22/19/22844\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8,21\">",
"     8,21",
"    </a>",
"    ]. Severe chronic AR is typically associated with a longer diastolic murmur, a displaced left ventricular impulse, a wide pulse pressure, and the peripheral findings of a wide pulse pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\", section on 'Severity of AR'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Serial monitoring",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Chronic AR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of serial clinical and echocardiographic monitoring in patients with asymptomatic chronic AR varies with the severity of the disease, the LVEF, LV dimensions, the possible presence of a dilated ascending aorta in patients with a bicuspid aortic valve, and whether previous studies have revealed progressive disease (",
"    <a class=\"graphic graphic_table graphicRef53536 \" href=\"UTD.htm?22/19/22844\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommends the following approach [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]. By definition, left ventricular dilatation is seen only in severe AR (",
"    <a class=\"graphic graphic_table graphicRef53536 \" href=\"UTD.htm?22/19/22844\">",
"     table 4",
"    </a>",
"    ) unless the patient has coexistent myocardial disease. In addition to this schedule, echocardiography is also recommended if the patient becomes symptomatic or has equivocal symptoms or a decline in exercise tolerance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild chronic AR and normal LVEF &mdash; clinical evaluation yearly and routine echocardiography every two to three years.",
"     </li>",
"     <li>",
"      For stable severe chronic AR, LVEF &gt;50 percent, and LV end-systolic and diastolic dimensions &le;55 and &le;75 mm, respectively, monitoring frequency varies somewhat with LV dimensions:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      LV end-systolic dimension &lt;45 mm and end-diastolic dimension &lt;60 mm &mdash; clinical evaluation every 6 to 12 months, and echocardiography every 12 months; reevaluate and repeat echocardiography in three months if the patient is not stable or this is the initial study",
"     </li>",
"     <li>",
"      LV end-systolic dimension 45 to 50 mm and end-diastolic dimension 60 to 70 mm &mdash; clinical evaluation every six months, and echocardiography every 12 months; reevaluate and repeat echocardiography in three months if the patient is not stable or this is the initial study",
"     </li>",
"     <li>",
"      LV end-systolic dimension 50 to 55 mm and end-diastolic dimension 70 to 75 mm and normal hemodynamic response to exercise &mdash; clinical evaluation every six months and echocardiography every six months; reevaluate and repeat echocardiography in three months if the patient is not stable or this is the initial study",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines made no recommendation for serial monitoring in patients with moderate AR (",
"    <a class=\"graphic graphic_table graphicRef53536 \" href=\"UTD.htm?22/19/22844\">",
"     table 4",
"    </a>",
"    ). It seems reasonable to choose an intermediate schedule between mild AR and severe AR without LV dilatation, with clinical examination yearly and echocardiography every one to two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bicuspid valves and aortic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;When AR is due to a bicuspid aortic valve, there is the additional concern about dilatation of the aortic root",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascending aorta, which is present in the majority of patients and can lead to aneurysm formation or dissection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the proximal 3 to 4 cm of the aortic root is easily visualized with echocardiography, the midportion of the ascending aorta may not be; as a result, evaluation with magnetic resonance imaging (MRI) or computed tomography (CT) is often needed. Yearly testing is recommended in patients with an aortic root or ascending aortic diameter greater than 40 mm (",
"    <a class=\"graphic graphic_table graphicRef82459 \" href=\"UTD.htm?23/34/24107\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=see_link\">",
"     \"Clinical manifestations and diagnosis of bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Low-risk group",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all asymptomatic patients with an LV end-systolic dimension (by echocardiography) below 50 mm can expect to remain asymptomatic for the next few years. When the LV end-systolic dimension is between 41 and 49 mm, the risk of developing symptoms, LV dysfunction, or death ranges from 1 to 2 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/17\">",
"     17",
"    </a>",
"    ] to as high as 6 percent per year (",
"    <a class=\"graphic graphic_table graphicRef54569 \" href=\"UTD.htm?0/37/604\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients with an LV end-systolic dimension below 40 mm have no risk of these complications until the LV end-systolic dimension increases to a higher level [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar low risk (1 to 2 percent per year) is seen in patients with an LV end-diastolic volume less than 150",
"    <span class=\"nowrap\">",
"     mL/m2",
"    </span>",
"    or an LV end-systolic volume less than 60",
"    <span class=\"nowrap\">",
"     mL/m2",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1082?source=see_link&amp;anchor=H17#H17\">",
"     \"Echocardiographic evaluation of the aortic valve\", section on 'Aortic regurgitation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     High-risk group",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several high risk criteria have been identified. The",
"    <strong>",
"     yearly rate",
"    </strong>",
"    of developing LV dysfunction or becoming symptomatic and requiring surgery is:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 19 percent when the LV end-systolic dimension exceeds 50 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/17\">",
"       17",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Over 25 percent when the LV end-systolic dimension is greater than 55 mm [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An LV ejection fraction less than 50 percent during exercise or an LV end-diastolic dimension above 75 mm also identifies patients at high risk (",
"    <a class=\"graphic graphic_table graphicRef53536 \" href=\"UTD.htm?22/19/22844\">",
"     table 4",
"    </a>",
"    ). It has been estimated that asymptomatic patients with severe AR who have a reduced LVEF have a rate of progression to symptoms that warrant aortic valve replacement of more than 25 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of these factors was illustrated in the Mayo Clinic review cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/7\">",
"     7",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 10 year mortality was significantly higher than expected for an age and sex matched population (34 versus 25 percent); in addition, 47 percent developed heart failure and 62 percent required aortic valve surgery. In total, 75 percent had died or had surgery and 83 percent had had cardiovascular events.",
"     </li>",
"     <li>",
"      The increase in mortality was highest in patients with severe but transient symptoms (25 percent per year) but was also increased in those with mild symptoms and in asymptomatic patients with an LVEF &lt;55 percent or an end-systolic diameter &ge;25",
"      <span class=\"nowrap\">",
"       mm/m2",
"      </span>",
"      (5.8 to 7.8 percent per year) (",
"      <a class=\"graphic graphic_figure graphicRef58816 \" href=\"UTD.htm?9/48/9997\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Surgery significantly reduced cardiovascular mortality (hazard ratio 0.54).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The predictive value of objective measures of LV function was also demonstrated in a study of 104 asymptomatic or minimally symptomatic patients with AR and normal left ventricular function who were prospectively followed for an average of 7.3 years; radionuclide cineangiography and echocardiography were performed annually [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/22\">",
"     22",
"    </a>",
"    ]. Multivariate analysis revealed that the change in LVEF from rest to exercise, normalized for the change in end-systolic wall stress from rest to exercise",
"    <span class=\"nowrap\">",
"     (&Delta;LVEF",
"    </span>",
"    -",
"    <span class=\"nowrap\">",
"     &Delta;ESS",
"    </span>",
"    index) was the strongest predictor of subnormal left ventricular function, progression to symptoms, requirement for surgery, or sudden death. The rate of progression in the highest and lowest tertile to the end point of cardiac death, operable symptoms, or reduced LV performance was 13.3 and 1.8 percent per year, respectively.",
"   </p>",
"   <p>",
"    Borderline or even frank LV systolic dysfunction (LVEF &lt;50 percent) of short duration may not carry the same ominous prognosis as a prolonged period of LV dysfunction. If LV dysfunction is present for less than 14 months, corrective surgery can be expected to reverse the volume-overload state and to allow recovery of the ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/23\">",
"     23",
"    </a>",
"    ]. In contrast, more prolonged LV dysfunction, particularly in association with congestive symptoms, is usually predictive of a poor response to corrective surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4600874\">",
"    <span class=\"h3\">",
"     Concomitant mitral regurgitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of concomitant 3 or 4+ mitral regurgitation (MR) may be an additional indicator of high risk. A retrospective study of 756 patients with severe AR identified the presence of 3 or 4+ MR as an independent predictor of reduced survival [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/24\">",
"     24",
"    </a>",
"    ]. Survival at five years was 42 percent in those with 3 or 4+ MR and 70 percent in those with 0 to 2+ MR. Patients with 3 or 4+ MR who underwent AVR had higher survival rates than those with 3 or 4+ MR not undergoing surgery (RR 0.61, 95% CI 0.40 to 0.93). In patients with 3 or 4+ MR undergoing AVR, concomitant mitral valve repair was associated with better survival than no mitral surgery or mitral valve (RR 0.29, 95% CI 0.09 to 0.94).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is also a role for exercise testing and cardiac catheterization [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines (with 2008 update) on the management of patients with valvular heart disease included recommendations for the use of these techniques in patients with AR (",
"    <a class=\"graphic graphic_table graphicRef75256 \" href=\"UTD.htm?6/52/6989\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10595111\">",
"    <span class=\"h3\">",
"     Exercise stress testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guideline suggestion of exercise stress testing in chronic AR to assess functional capacity and symptom response in patients with equivocal symptoms (",
"    <a class=\"graphic graphic_table graphicRef75256 \" href=\"UTD.htm?6/52/6989\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]. Exercise testing is also reasonable to assess functional capacity and symptoms prior to athletic activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10594952\">",
"    <span class=\"h3\">",
"     Role of preoperative coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended cardiac catheterization in patients with chronic aortic regurgitation in only two settings: when noninvasive tests are inconclusive or provide discrepant results from clinical findings (",
"    <a class=\"graphic graphic_table graphicRef75256 \" href=\"UTD.htm?6/52/6989\">",
"     table 2",
"    </a>",
"    ); or when there is a need to assess coronary anatomy before aortic valve replacement because of a risk for coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coronary angiography was recommended in the following settings in patients who are not severely hemodynamically unstable (",
"    <a class=\"graphic graphic_table graphicRef66360 \" href=\"UTD.htm?29/4/29772\">",
"     table 6",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before valve surgery in patients with chest pain, other objective evidence of ischemia or a history of coronary disease.",
"     </li>",
"     <li>",
"      Before valve surgery in patients at risk for coronary disease, which was defined as men &ge;35 years of age, premenopausal women &ge;35 years of age who have coronary risk factors, and postmenopausal women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The evidence was considered less well established for coronary angiography before valve surgery in the absence of these indications when cardiac catheterization is considered necessary to confirm the severity of the aortic regurgitation.",
"   </p>",
"   <p>",
"    However, based upon these guidelines, many patients without significant coronary disease will undergo coronary angiography. Better methods are needed to identify patients at low risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10595029\">",
"    <span class=\"h4\">",
"     Noninvasive coronary angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible alternative is noninvasive coronary angiography, which may be accomplished using coronary computed tomography angiography (CCTA) or cardiovascular magnetic resonance (CMR) imaging. The current utility of these tests as an alternative to conventional selective coronary angiography is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=see_link\">",
"     \"Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data are limited in patients with AR. The ability of CCTA to exclude significant coronary artery disease using a 64-slice scanner was investigated in 70 patients referred for cardiac valve surgery, nine of whom had AR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/27\">",
"     27",
"    </a>",
"    ]. The prevalence of significant coronary artery disease, defined as the presence of at least one lesion with stenosis diameter of &ge;50 percent, was 26 percent. The sensitivity of CCTA was 100 percent.",
"   </p>",
"   <p>",
"    Further study is required before this approach can be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PHYSICAL ACTIVITY AND EXERCISE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The regurgitant volume in patients with AR decreases with exercise. This effect is mediated by two factors: a fall in diastolic pressure due to the reduction in peripheral vascular resistance; and a decrease in the diastolic filling period due to the increase in heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/28\">",
"     28",
"    </a>",
"    ]. On the other hand, the left ventricular ejection fraction does not show the normal increase during exercise, a change that is of uncertain significance given the reduction in regurgitant volume.",
"   </p>",
"   <p>",
"    Each patient's exercise tolerance will vary with the severity of their disease (",
"    <a class=\"graphic graphic_table graphicRef53536 \" href=\"UTD.htm?22/19/22844\">",
"     table 4",
"    </a>",
"    ) and the intensity and type of exercise (",
"    <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/29\">",
"     29",
"    </a>",
"    ]. Taking these factors into account and the association of AR with aortic root dilatation in some patients, specific recommendations for participation in competitive sports in patients with AR were made by the 36th Bethesda Conference [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic patients with mild or moderate AR with a left ventricular end-diastolic diameter that is normal (&le;55 mm) or mildly increased can participate in all competitive sports.",
"     </li>",
"     <li>",
"      Selected patients with AR and a moderate increase in left ventricular end-diastolic diameter (60 to 65 mm) can participate in low and moderate static sports and all dynamic sports (class IA, IB, IC, IIA, IIB, or IIC) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 2",
"      </a>",
"      ) if exercise testing to at least the level of activity achieved in competition produces neither symptoms nor ventricular arrhythmias.",
"     </li>",
"     <li>",
"      Patients with asymptomatic nonsustained ventricular tachycardia at rest or with exercise should only participate in low-intensity competitive sports (class IA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Asymptomatic patients with severe AR and a left ventricular end-diastolic diameter greater than 65 mm (",
"      <a class=\"graphic graphic_table graphicRef53536 \" href=\"UTD.htm?22/19/22844\">",
"       table 4",
"      </a>",
"      ) and patients with mild or moderate AR who have symptoms (regardless of left ventricular end-diastolic diameter) should not participate in competitive sports.",
"     </li>",
"     <li>",
"      Patients with AR and significant dilatation of the ascending aorta (&gt;45 mm, normal &le;35 mm) should participate only in low-intensity competitive sports (class IA) (",
"      <a class=\"graphic graphic_figure graphicRef64493 \" href=\"UTD.htm?28/51/29489\">",
"       figure 2",
"      </a>",
"      ). This recommendation does not apply to patients with Marfan syndrome in whom any degree of aortic dilatation should prohibit competitive sports because of the risk of aortic dissection and rupture. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=see_link&amp;anchor=H20#H20\">",
"       \"Risk of sudden cardiac death in athletes\", section on 'Marfan syndrome'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recommendations for exercise in patients with bicuspid aortic valves who have aortic root dilatation are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\", section on 'Physical activity and exercise'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasodilators such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    and angiotensin converting enzyme (ACE) inhibitors may influence LV size and function and slow the rate of progression of AR. The evidence of benefit is greatest in symptomatic patients with significant LV dilation. Randomized trials have produced conflicting findings as to whether there is or is not a benefit from vasodilator therapy among asymptomatic patients with severe chronic AR, LV dilation, and normal LV systolic function. Use of vasodilators in patients with chronic AR is discussed in detail separately (",
"    <a class=\"graphic graphic_table graphicRef79823 \" href=\"UTD.htm?4/39/4732\">",
"     table 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14567?source=see_link\">",
"     \"Vasodilator therapy in severe chronic aortic regurgitation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other forms of medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy, other than vasodilators, has a limited role in AR because symptomatic patients should be treated with valve replacement. For those patients who develop symptoms of heart failure but are not candidates for surgery, therapy is similar to that for other causes of heart failure (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    for symptoms, diuretics for fluid control, ACE inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angiotensin II receptor blockers to improve survival). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a relative contraindication to beta blockers in patients with AR because slowing the heart rate may increase the regurgitant volume by prolonging diastole. Similar concerns about excess slowing of the ventricular rate also apply to rate control with atrioventricular nodal blockers in the infrequent patients who develop atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is one setting in which beta blockers may be considered. The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of valvular heart disease concluded that beta blocker therapy was reasonable in patients with bicuspid aortic valves who have an aortic root diameter greater than 40 mm and do NOT have moderate or severe aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With respect to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy, we agree with the recommendations from the Eighth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy that long-term anticoagulation is",
"    <strong>",
"     not",
"    </strong>",
"    recommended unless there are other indications for anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ENDOCARDITIS PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 American Heart Association guidelines on infective endocarditis revised prior recommendations for patients with acquired valvular disease, including those with chronic AR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/31\">",
"     31",
"    </a>",
"    ]. As a result, antibiotic prophylaxis is",
"    <strong>",
"     no longer",
"    </strong>",
"    recommended when such patients undergo dental or other invasive procedures that produce significant bacteremia with organisms associated with endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of patients with valvular heart disease included a classification of specific valve lesions and clinical settings as high or low maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      AR is considered high risk if associated with New York Heart Association (NYHA) class III to IV symptoms (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 8",
"      </a>",
"      ), an LVEF less than 40 percent, or Marfan syndrome. Ideally, such patients should receive definitive surgical therapy before pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=see_link\">",
"       \"Pregnancy and Marfan syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      AR is considered low risk if associated with normal left ventricular systolic function and NYHA class I or II symptoms (",
"      <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"       table 8",
"      </a>",
"      ). Such women generally tolerate pregnancy without complications. The normal fall in systemic vascular resistance that occurs during pregnancy may be beneficial by decreasing the degree of regurgitation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptomatic patients can be treated with diuretics and, if necessary, vasodilators (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ). Angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers should be discontinued during pregnancy, because of potential harm to the fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link\">",
"     \"Management of heart failure in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Vasodilators'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=see_link\">",
"     \"Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnant women with AR due to Marfan syndrome are at risk for aortic dissection, particularly those who already have aortic root dilatation. The prophylactic use of beta blockers may minimize aortic dilation during pregnancy in such patients.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     Labetalol",
"    </a>",
"    may be the preferred beta blocker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=see_link\">",
"     \"Pregnancy and Marfan syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H22#H22\">",
"     \"Management of hypertension in pregnant and postpartum women\", section on 'Choice of drug'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to pregnancy in women with AR due to a bicuspid aortic valve are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27032?source=see_link\">",
"     \"Pregnancy in women with a bicuspid aortic valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac surgery should be avoided, if possible, during pregnancy. The maternal risks are about the same as those in nonpregnant women, but cardiopulmonary bypass during pregnancy poses problems for the fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link&amp;anchor=H13#H13\">",
"     \"Pregnancy in women with congenital heart disease: General principles\", section on 'Cardiac surgery during pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a woman with AR presents early in pregnancy with one or more of the high risk features described above, we recommend termination of pregnancy followed by corrective surgery before another attempt at pregnancy. If the mother declines termination, we manage the patient medically and, as recommended by the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, operate only for refractory NYHA class III or IV symptoms (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]. It is preferable to delay surgery, if possible, until the fetus is viable; a cesarean section can then be performed as part of a combined procedure.",
"   </p>",
"   <p>",
"    The guidelines recommend that the criteria described in the next section for aortic valve surgery in less symptomatic or asymptomatic patients, which are based upon left ventricular size and the left ventricular ejection fraction, should",
"    <strong>",
"     not",
"    </strong>",
"    be applied to pregnant patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     AORTIC VALVE REPLACEMENT OR REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on the management of patients with valvular heart disease included recommendations for aortic valve replacement or repair in patients with AR (",
"    <a class=\"graphic graphic_table graphicRef81155 \" href=\"UTD.htm?23/53/24412\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57010 \" href=\"UTD.htm?39/4/40011\">",
"     table 10",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]. Similar recommendations were made in the 2007 European Society of Cardiology (ESC) management of patients with valvular heart disease of [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines noted that, although aortic valve replacement is performed in most patients, there is increasing experience in some centers with aortic valve repair in selected patients. The guideline recommendations applied the term AVR to both valve replacement and valve repair. However, most of the data presented below is on aortic valve replacement, since there is a much greater experience than with valve repair, particularly in older adults. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Aortic valve repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve replacement or repair is indicated in symptomatic patients with severe chronic AR (",
"    <a class=\"graphic graphic_table graphicRef81155 \" href=\"UTD.htm?23/53/24412\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57010 \" href=\"UTD.htm?39/4/40011\">",
"     table 10",
"    </a>",
"    ). Surgical correction of the regurgitant lesion usually produces at least some improvement in symptoms, regardless of the functional state of the ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In one study of symptomatic patients, for example, 12 of 14 had a decrease in symptoms and increase in LVEF into the normal range (average 59 percent) following valve replacement, despite an average preoperative LVEF of 45 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Waiting for the patient to develop exercise intolerance or dyspnea may result in some degree of irreversible LV dysfunction. Furthermore, the combination of LV dysfunction and symptoms of heart failure generally precludes an optimal surgical result (",
"    <a class=\"graphic graphic_figure graphicRef60791 \" href=\"UTD.htm?16/41/17054\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef82155 \" href=\"UTD.htm?0/43/702\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For this reason, the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended aortic valve replacement or aortic valve repair in asymptomatic patients with chronic severe AR who have reliable evidence of LV systolic dysfunction (eg, LVEF &lt;50 percent). In addition, the guidelines indicated that aortic valve replacement is reasonable in asymptomatic patients if LVEF is &gt;50 percent and LV end-systolic dimension &gt;55 mm, or LV end-diastolic dimension &gt;75 mm (",
"    <a class=\"graphic graphic_table graphicRef81155 \" href=\"UTD.htm?23/53/24412\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57010 \" href=\"UTD.htm?39/4/40011\">",
"     table 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8,37\">",
"     8,37",
"    </a>",
"    ]. Lower threshold values for LV end-systolic (&gt;50 mm) and end-diastolic (&gt;70 mm) dimensions were recommended by the ESC guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/32\">",
"     32",
"    </a>",
"    ] and, in the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines, could be considered in patients of small stature [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some consideration of body size should be included in any estimation of LV dimension, since smaller women are less likely to reach the above criteria that were established in men [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/16,38\">",
"     16,38",
"    </a>",
"    ]. However, simply normalizing for body surface area can lead to misleading conclusions, especially in obese patients. In general, somewhat lower values should be used in very small patients and somewhat higher values in very large patients.",
"   </p>",
"   <p>",
"    These breakpoints are not absolute and patients with borderline values (eg, LVEF between 50 and 55 percent) need careful monitoring. Clinical evaluation and echocardiography should be performed at six month intervals and consideration given to assessing the hemodynamic response to exercise. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Serial monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Surgical replacement of the aortic valve is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in a truly asymptomatic patient with normal LV function (LVEF &ge;50 percent) without severe LV dilatation. Early surgery exposes the patient to perioperative mortality (that averages 4 percent compared to &lt;0.2 percent per year without surgery) and morbidity and to the long-term complications of a prosthetic heart valve [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Such patients should undergo periodic echocardiographic assessment for signs of progressive disease that would warrant valve replacement. Asymptomatic patients with moderate to severe AR and a normal LVEF at baseline require aortic valve replacement at the rate of approximately",
"    <strong>",
"     4 percent per year",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Serial monitoring'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H4\">",
"     'Stages and course'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For reasons that are not well understood, valve replacement in women is most often performed for symptoms and only rarely for left ventricular enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term impact of adhering to the guideline recommendations for aortic valve replacement in asymptomatic patients is described below [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Importance of timing of surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Aortic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;When AR is due to a bicuspid aortic valve, there is the additional concern about dilatation of the aortic root",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ascending aorta, which is present in the majority of patients and can lead to aneurysm formation or dissection. As a result, surgery may be indicated for aortic disease as well as chronic AR. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Bicuspid valves and aortic disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=see_link\">",
"     \"Treatment of bicuspid aortic valve stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines made the following recommendations in patients with bicuspid aortic valves [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]. For each of the threshold aortic root or ascending aorta diameters, lower values may be considered in men or women of small stature.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients undergoing aortic valve replacement or repair, concurrent repair of the aortic root or replacement of the ascending aorta is indicated if the aortic root and ascending aorta diameter is greater than 45 mm.",
"     </li>",
"     <li>",
"      Independent of the need for aortic valve replacement or repair, repair of the aortic root or replacement of the ascending aorta is indicated if the aortic root and ascending aorta diameter is greater than 50 mm or the rate of increase is &ge;5 mm per year.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The guidelines also concluded that the weight of evidence or opinion was in favor of the administration of beta blockers to patients with an aortic root diameter greater than 40 mm who are not candidates for surgery and do not have moderate or severe AR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Choice of valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;When valve replacement is performed, either a mechanical or bioprosthetic valve can be used. The choice between these valves is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11865?source=see_link&amp;anchor=H3#H3\">",
"     \"Surgical valve replacement in aortic stenosis in adults\", section on 'Mechanical versus bioprosthetic valve'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, we agree with the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines which recommended that patient age, ability to tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , and patient preference all be taken into account (",
"    <a class=\"graphic graphic_table graphicRef63902 \" href=\"UTD.htm?9/61/10204\">",
"     table 11",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with a projected long life-span generally receive a mechanical valve because of far greater durability and improved patient survival at 15 years [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The main indications for a bioprosthesis are patients who cannot or will not tolerate",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or for whom compliance is uncertain, and patients &ge;65 years of age who do not have risk factors for thromboembolism since valve durability is less of an issue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Operative mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative mortality in patients with pure AR who undergo isolated aortic valve replacement is relatively low in experienced centers but increases if the LVEF is reduced, concomitant coronary artery bypass graft surgery or aortic root replacement, or the patient has significant comorbidities, such as older age [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These relationships were illustrated in a retrospective analysis of 450 patients form the Mayo Clinic who underwent aortic valve replacement for isolated chronic AR between 1980 and 1995; the LVEF was &lt;35 percent in 43, between 35 and 50 percent in 134, and &ge;50 percent in 273 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/9\">",
"     9",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the 242 patients who underwent isolated aortic valve replacement without an associated procedure, the patients with a low LVEF had a significant increase in operative mortality (7.7 versus 4.2 and 2.1 percent in patients with moderately reduced or normal LVEF, respectively).",
"     </li>",
"     <li>",
"      Operative mortality was significantly higher in the 208 patients who also underwent coronary artery bypass graft",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ascending aortic repair (23.5, 9.5, and 5.5 percent, respectively, in the three LVEF groups).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A lower operative mortality with isolated aortic valve replacement (0.75 percent) was noted in a report of 266 patients who had participated in a randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    versus placebo but had undergone isolated aortic valve replacement because of progression to an LVEF below 50 percent (mean 46 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Risk stratification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding discussion has emphasized that a variety of factors affect the risk for in-hospital mortality after aortic valve replacement. The most effective way of stratifying operative risk is by using one of the available validated risk stratification models. As noted above, a variety of factors affect the risk of mortality after aortic valve replacement. The risk models are helpful in the evaluation and counseling of individual patients and planning perioperative care. Models have been developed to estimate risk of in-hospital mortality and complications following aortic or mitral valve surgery with or without coronary artery bypass graft surgery (CABG). These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/5/7252?source=see_link\">",
"     \"Estimating the mortality risk of valvular surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Postoperative monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;An echocardiogram should be performed before hospital discharge or preferably at the first postdischarge outpatient visit [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]. A good predictor of the eventual improvement in left ventricular function is the reduction in left ventricular end-diastolic dimension, approximately 80 percent of which occurs in the first 10 to 14 days after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8,42,43\">",
"     8,42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommends the following approach to ongoing postoperative monitoring [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]. After the first postoperative evaluation, patients with an uncomplicated course should be seen at 6 and 12 months and then yearly. Routine serial echocardiography is not usually indicated if the first postoperative echocardiogram shows a substantial reduction in left ventricular end-diastolic dimension, the LVEF is normal, and the patient is asymptomatic. Echocardiography is warranted if the patient develops a new murmur or there are concerns about prosthetic valve integrity or left ventricular function.",
"   </p>",
"   <p>",
"    Patients with persistent left ventricular dilatation should be treated the same as other patients with asymptomatic or symptomatic left ventricular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=see_link\">",
"     \"Evaluation and management of asymptomatic left ventricular systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Long-term outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The long-term outcome is relatively good in patients with pure AR after aortic valve replacement. This was illustrated in a review of 125 patients who were followed for 13.3 years; the mortality rate after surgery was stable at 2.5 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/44\">",
"     44",
"    </a>",
"    ]. Predictors of long-term survival were younger age, lower preoperative NYHA class, a preoperative angiographic end-systolic index less than 120",
"    <span class=\"nowrap\">",
"     mL/m2,",
"    </span>",
"    and a postoperative reduction in end-diastolic dimension or more than 20 percent.",
"   </p>",
"   <p>",
"    The long-term outcome is influenced by the timing of surgery, the LVEF before surgery, gender, and perhaps prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Importance of timing of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact on long-term outcome of adhering to the above guideline recommendations for aortic valve replacement for chronic severe AR in asymptomatic patients was evaluated in a prospective cohort of 170 patients: 60 underwent recommended early surgery and 110 underwent \"too late\" surgery as defined by severe symptoms, an LVEF less than 45 percent (mean 42 percent), or an end-systolic dimension &gt;55 mm [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Indications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    At a mean follow-up of 10 years, cardiac mortality was significantly higher in the patients who underwent \"too late\" surgery (28 versus 9 percent [28 versus 5 patients]). The increase in cardiac mortality was largely due to more deaths from heart failure or sudden death (20 versus 1). The difference in overall survival was 75 versus 90 percent at five years and 64 versus 86 percent at 10 years.",
"   </p>",
"   <p>",
"    This study also provided support for surgery before the onset of severe symptoms. All patients who underwent early surgery and 44 of the 110 who underwent \"too late\" surgery had no or only mild symptoms (NYHA class I or II) (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 8",
"    </a>",
"    ). The remaining patients in the latter group who were in NYHA class III or IV had, compared to those with no or only mild symptoms, significant increases in both operative mortality (14 versus 3 percent) and long-term cardiac mortality (35 versus 10 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     LVEF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic AR who have a low LVEF have a worse outcome if treated conservatively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/7,22,39\">",
"     7,22,39",
"    </a>",
"    ]. Valve replacement is recommended in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ], even though the outcome is worse than in patients with a normal LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/9,13,39\">",
"     9,13,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic importance of LVEF on long-term outcome was evaluated in the retrospective analysis from the Mayo Clinic cited above of 450 patients who underwent surgery between 1980 and 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/9\">",
"     9",
"    </a>",
"    ]. The outcome after aortic valve replacement was stratified by LVEF at the time of surgery: less than 35 percent, between 35 and 50 percent, and &ge;50 percent. The following findings were noted in the patients with an LVEF below 35 percent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant reduction in 10-year survival (41 versus 56 and 70 percent in patients with an LVEF between 35 and 50 percent, and &ge;50 percent, respectively).",
"     </li>",
"     <li>",
"      A significant increase in the development of heart failure at 10 years (25 versus 17 and 9 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the excess mortality and morbidity in the patients with markedly reduced left ventricular function, there was a 4.9 percent increase in LVEF after surgery and most patients had prolonged survival without progression to heart failure. Thus, even though a controlled trial has not been performed, the authors and others have recommended that such patients should not be denied the benefit of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/9,37\">",
"     9,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Later data suggest that the LVEF may not be a predictor of outcome in patients with chronic AR who undergo surgery. This was illustrated in a retrospective, observational report of 77 well-matched pairs of patients with chronic AR (LVEF &le;30 or &gt;30 percent) who underwent aortic valve replacement between 1972 and 1999 at the Cleveland Clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/45\">",
"     45",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survival of patients with severely depressed LVEF significantly improved across the study time due in large part to a reduction in in-hospital mortality (0 percent in both groups after 1985).",
"     </li>",
"     <li>",
"      In patients operated on after 1985, survival at 1, 5, and 10 years was similar in patients with LVEF &le;30 compared to those with LVEF &gt;30 percent (92 versus 96 percent, 79 versus 83 percent, and 51 versus 55 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women have a poorer outcome after aortic valve replacement when compared to men [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/38,46\">",
"     38,46",
"    </a>",
"    ]. This was illustrated in a report of 51 women and 198 men undergoing aortic valve replacement for pure AR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/38\">",
"     38",
"    </a>",
"    ]. Although the operative mortality was the same for women and men (3.9 versus 4.5 percent), women had a lower 10-year survival (39 versus 72 percent). Women more often had surgery for severe symptoms, but rarely for severe left ventricular enlargement which, as noted above, is one of the major indications for surgery in men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Aortic valve repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, there is increasing experience with aortic valve repair for the treatment of chronic AR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/27,47-50\">",
"     27,47-50",
"    </a>",
"    ] and the",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines apply the term AVR to both aortic valve replacement and repair (",
"    <a class=\"graphic graphic_table graphicRef81155 \" href=\"UTD.htm?23/53/24412\">",
"     table 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef57010 \" href=\"UTD.htm?39/4/40011\">",
"     table 10",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]. Use of aortic valve repair is primarily limited to AR due to aortic root dilatation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    excess cusp motion since repair of retracted or heavily calcified valves (such as rheumatic valves) has not provided long-term success [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/47,51\">",
"     47,51",
"    </a>",
"    ]. Aortic valve repair may consist of an isolated aortic valve sparing operation, an isolated aortic cusp repair, or a combination of these procedures.",
"   </p>",
"   <p>",
"    The predictive value of aortic valve anatomy for valve repairability was evaluated in a study of 163 patients undergoing surgery for AR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/47\">",
"     47",
"    </a>",
"    ]. The mechanism of aortic regurgitation was classified as due to aortic root dilatation (type 1), excess cusp motion, including cusp prolapse and cusp fenestrations, with good cusp tissue quality (type 2), or poor cusp tissue quality including cusp retraction, extensive cusp calcifications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endocarditis (type 3). Type 1 and 2 lesions were considered repairable unless cusp body calcification was present, while type 3 lesions were considered nonrepairable. Transesophageal echocardiography classification of lesion type agreed strongly with surgical inspection (93 percent) and was strongly predictive of valve repairability and postoperative outcome.",
"   </p>",
"   <p>",
"    Aortic valve repair has the major advantages compared to aortic valve replacement of low thromboembolic risk, which avoids the need for chronic anticoagulation, preservation of a near normal aortic valve orifice, and the potential for a less complicated reoperation. The main disadvantages are a higher rate of reoperation (about 15 percent at ten years) and less widespread experience [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"     8",
"    </a>",
"    ]. Valve repair has more often been performed in young patients (",
"    <a class=\"graphic graphic_table graphicRef57010 \" href=\"UTD.htm?39/4/40011\">",
"     table 10",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The outcomes after aortic valve repair were evaluated in a 2004 report from the Mayo Clinic of 160 patients who underwent repair procedures, there was one early death, a need for repeat repair during the initial hospitalization, and 16 late deaths at a mean follow-up of 4.2 years, only two of which might have been related to AR [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/48\">",
"     48",
"    </a>",
"    ]. The survival rate was similar to that of an age- and sex-matched control population. Reoperation, primarily aortic valve replacement for severe AR, was required in 9, 11, and 15 percent of patients at three, five, and seven years, respectively.",
"   </p>",
"   <p>",
"    Another study compared the short-term outcomes in 44 patients with a bicuspid aortic valve and chronic AR who underwent valve repair to 44 patients matched for age and left ventricular function who underwent valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/49\">",
"     49",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There were no early or late deaths in either groups",
"     </li>",
"     <li>",
"      Mild AR in the early postoperative period was present in nine patients who underwent repair and five who underwent valve replacement.",
"     </li>",
"     <li>",
"      Freedom from repeat valve surgery at five years for progressive AR or endocarditis was similar in the two groups: 91 versus 94 percent. However, freedom form moderate to severe AR at five years was significantly lower with valve repair (79 versus 94 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Minimally invasive surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only limited data on the use of minimally invasive aortic valve surgery in patients with AR. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/38/30310?source=see_link\">",
"     \"Minimally invasive aortic and mitral valve surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Takayasu arteritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both aortic valve replacement and valve repair have been performed in patients with AR due to Takayasu arteritis. Late valve or graft detachment and late dilation of the residual ascending aorta occur in a minority of patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3015?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of Takayasu arteritis\", section on 'Aortic valve surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     AORTIC ROOT DILATATION AND MARFAN SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients with aortic root disease, such as Marfan syndrome, aortic dissection, or Takayasu arteritis, the degree of AR may be mild or the left ventricle is only mildly dilated. In such patients, treatment should be directed at the aortic root disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/52\">",
"     52",
"    </a>",
"    ]. On the other hand, treatment should be directed at both disorders if the AR is severe.",
"   </p>",
"   <p>",
"    In patients with an aortic root diameter greater than 55 mm (normal &le;35 mm), surgery should be performed without consideration of the degree of AR or left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/32\">",
"     32",
"    </a>",
"    ]. Among patients with Marfan syndrome, elective surgical correction at an aortic root diameter &ge;50 mm, particularly if a rapid increase in aortic root diameter is noted or a valve-sparing operation is possible. Values greater than 40 mm identify women with Marfan syndrome at increased risk for aortic complications during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link\">",
"     \"Management of Marfan syndrome and related disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=see_link\">",
"     \"Pregnancy and Marfan syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Aortic valve-sparing reimplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve-sparing reimplantation or aortic valve resuspension is a valve-sparing technique used in patients with AR due to aortic root dilatation in which valvular insufficiency is due to outward displacement of the valve commissures. This technique, which is different from aortic valve repair described above, has the advantages of lack of requirement for anticoagulation and avoidance of the other problems and complications associated with mechanical prosthetic valves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although primarily used for secondary AR due to aortic root dilatation as occurs in Marfan syndrome, aortic valve-sparing reimplantation has also been used for type A acute aortic dissections [",
"    <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Limited data suggest that this approach is more difficult in Takayasu arteritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link\">",
"     \"Management of Marfan syndrome and related disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3015?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of Takayasu arteritis\", section on 'Aortic valve surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following tests are useful in the evaluation of patients with AR (",
"      <a class=\"graphic graphic_table graphicRef75256 \" href=\"UTD.htm?6/52/6989\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"       8",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with AR should have an initial echocardiogram with periodic follow-up examinations (",
"      <a class=\"graphic graphic_movie graphicRef52651 \" href=\"UTD.htm?30/9/30867\">",
"       movie 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef79209 \" href=\"UTD.htm?21/28/21954\">",
"       movie 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef55154 \" href=\"UTD.htm?21/47/22260\">",
"       movie 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef65848 \" href=\"UTD.htm?29/38/30306\">",
"       movie 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exercise testing may be helpful for assessing functional capacity and symptom response when symptoms are equivocal or prior to participation in athletics. (See",
"      <a class=\"local\" href=\"#H10595111\">",
"       'Exercise stress testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cardiac catheterization with angiography or radionuclide ventriculography is indicated if there is uncertainty about the functional state of the ventricle or the presence of associated disease (eg, coronary artery disease). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Other testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The clinical examination, exercise tolerance, and LV size and function are monitored closely in patients with chronic AR who are not yet candidates for surgery. In the absence of symptoms, management decisions are largely based upon serial measurements of LV size and function. Annual echocardiographic studies are indicated in all patients with clinically significant AR. Less-frequent studies may be indicated if the LV size and function remain stable over several years of follow-up.",
"     </li>",
"     <li>",
"      Aortic valve replacement or repair is indicated in symptomatic patients with chronic AR (",
"      <a class=\"graphic graphic_table graphicRef81155 \" href=\"UTD.htm?23/53/24412\">",
"       table 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef57010 \" href=\"UTD.htm?39/4/40011\">",
"       table 10",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aortic valve replacement or repair is indicated in asymptomatic patients with chronic severe AR who have reliable evidence of LV systolic dysfunction (LVEF &lt;50 percent). (",
"      <a class=\"graphic graphic_table graphicRef81155 \" href=\"UTD.htm?23/53/24412\">",
"       table 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef57010 \" href=\"UTD.htm?39/4/40011\">",
"       table 10",
"      </a>",
"      ). In addition, aortic valve replacement is suggested in asymptomatic patients if LVEF is &gt;50 percent and LV end-systolic dimension &gt;55 mm, or LV end-diastolic dimension &gt;75 mm (",
"      <a class=\"graphic graphic_table graphicRef81155 \" href=\"UTD.htm?23/53/24412\">",
"       table 9",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef57010 \" href=\"UTD.htm?39/4/40011\">",
"       table 10",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgery should be considered in asymptomatic patients who show progressive LV enlargement, particularly if the end-diastolic dimension exceeds 70 mm, the systolic dimension approaches 50 mm, or the ejection fraction approaches 50 percent (",
"      <a class=\"graphic graphic_table graphicRef69635 \" href=\"UTD.htm?7/8/7308\">",
"       table 3",
"      </a>",
"      ). Alternatively, vasodilator therapy can be used to reduce the hemodynamic burden and possibly delay the need for surgery. Many such patients will need surgery within the ensuing years, but the original decision on medical versus surgical therapy should be made in conjunction with the patient's wishes and expectations. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Vasodilators'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence of LV systolic dysfunction (ie, LVEF &lt;50 percent, not merely LV enlargement) indicates that the patient may be entering a decompensated stage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Vasodilator therapy can reduce the hemodynamic burden, but aortic valve replacement is indicated even in the absence of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who are symptomatic with LV dysfunction should undergo valve replacement after a period of intense medical treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      , diuretics, and a vasodilator to eliminate congestive symptoms.",
"     </li>",
"     <li>",
"      Evidence supports aortic valve replacement in patients who present late with severely depressed left ventricular systolic function (LVEF &le;30 percent). However, factors such as gender, estimated surgical risk, and expertise of the surgeon and institution need to be taken into account. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Long-term outcome'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H31\">",
"       'Aortic valve repair'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Randomized trials have produced conflicting findings as to whether there is or is not a benefit from vasodilator therapy (ACE inhibitor or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       nifedipine",
"      </a>",
"      ) among asymptomatic patients with severe AR, LV dilation, and normal LV systolic function. In comparison, there is no evidence supporting vasodilator therapy in asymptomatic patients with severe AR without LV dilation or those with mild to moderate AR. The possible role of vasodilators is discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14567?source=see_link\">",
"       \"Vasodilator therapy in severe chronic aortic regurgitation in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/1\">",
"      SEGAL J, HARVEY WP, HUFNAGEL C. A clinical study of one hundred cases of severe aortic insufficiency. Am J Med 1956; 21:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/2\">",
"      Spagnuolo M, Kloth H, Taranta A, et al. Natural history of rheumatic aortic regurgitation. Criteria predictive of death, congestive heart failure, and angina in young patients. Circulation 1971; 44:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/3\">",
"      Goldschlager N, Pfeifer J, Cohn K, et al. The natural history of aortic regurgitation. A clinical and hemodynamic study. Am J Med 1973; 54:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/4\">",
"      Rapaport E. Natural history of aortic and mitral valve disease. Am J Cardiol 1975; 35:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/5\">",
"      Schwarz F, Baumann P, Manthey J, et al. The effect of aortic valve replacement on survival. Circulation 1982; 66:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/6\">",
"      Gaasch WH, Sundaram M, Meyer TE. Managing asymptomatic patients with chronic aortic regurgitation. Chest 1997; 111:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/7\">",
"      Dujardin KS, Enriquez-Sarano M, Schaff HV, et al. Mortality and morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. Circulation 1999; 99:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/8\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/9\">",
"      Chaliki HP, Mohty D, Avierinos JF, et al. Outcomes after aortic valve replacement in patients with severe aortic regurgitation and markedly reduced left ventricular function. Circulation 2002; 106:2687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/10\">",
"      Gaasch WH, Andrias CW, Levine HJ. Chronic aortic regurgitation: the effect of aortic valve replacement on left ventricular volume, mass and function. Circulation 1978; 58:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/11\">",
"      Schuler G, Peterson KL, Johnson AD, et al. Serial noninvasive assessment of left ventricular hypertrophy and function after surgical correction of aortic regurgitation. Am J Cardiol 1979; 44:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/12\">",
"      Borow KM, Green LH, Mann T, et al. End-systolic volume as a predictor of postoperative left ventricular performance in volume overload from valvular regurgitation. Am J Med 1980; 68:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/13\">",
"      Henry WL, Bonow RO, Borer JS, et al. Observations on the optimum time for operative intervention for aortic regurgitation. I. Evaluation of the results of aortic valve replacement in symptomatic patients. Circulation 1980; 61:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/14\">",
"      Kumpuris AG, Quinones MA, Waggoner AD, et al. Importance of preoperative hypertrophy, wall stress and end-systolic dimension as echocardiographic predictors of normalization of left ventricular dilatation after valve replacement in chronic aortic insufficiency. Am J Cardiol 1982; 49:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/15\">",
"      Gaasch WH, Carroll JD, Levine HJ, Criscitiello MG. Chronic aortic regurgitation: prognostic value of left ventricular end-systolic dimension and end-diastolic radius/thickness ratio. J Am Coll Cardiol 1983; 1:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/16\">",
"      Stone PH, Clark RD, Goldschlager N, et al. Determinants of prognosis of patients with aortic regurgitation who undergo aortic valve replacement. J Am Coll Cardiol 1984; 3:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/17\">",
"      Bonow RO, Rosing DR, McIntosh CL, et al. The natural history of asymptomatic patients with aortic regurgitation and normal left ventricular function. Circulation 1983; 68:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/18\">",
"      Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term assessment of the natural history of asymptomatic patients with chronic aortic regurgitation and normal left ventricular systolic function. Circulation 1991; 84:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/19\">",
"      Siemienczuk D, Greenberg B, Morris C, et al. Chronic aortic insufficiency: factors associated with progression to aortic valve replacement. Ann Intern Med 1989; 110:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/20\">",
"      Devlin WH, Petrusha J, Briesmiester K, et al. Impact of vascular adaptation to chronic aortic regurgitation on left ventricular performance. Circulation 1999; 99:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/21\">",
"      Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003; 16:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/22\">",
"      Borer JS, Hochreiter C, Herrold EM, et al. Prediction of indications for valve replacement among asymptomatic or minimally symptomatic patients with chronic aortic regurgitation and normal left ventricular performance. Circulation 1998; 97:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/23\">",
"      Bonow RO, Rosing DR, Maron BJ, et al. Reversal of left ventricular dysfunction after aortic valve replacement for chronic aortic regurgitation: influence of duration of preoperative left ventricular dysfunction. Circulation 1984; 70:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/24\">",
"      Pai RG, Varadarajan P. Prognostic implications of mitral regurgitation in patients with severe aortic regurgitation. Circulation 2010; 122:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/25\">",
"      De Rito V, Natali R, Vigna C, et al. Analysis of agreement between dobutamine stress echocardiography and exercise nuclear angiography in severe aortic regurgitation. Am J Cardiol 2000; 86:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/26\">",
"      Wahi S, Haluska B, Pasquet A, et al. Exercise echocardiography predicts development of left ventricular dysfunction in medically and surgically treated patients with asymptomatic severe aortic regurgitation. Heart 2000; 84:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/27\">",
"      Meijboom WB, Mollet NR, Van Mieghem CA, et al. Pre-operative computed tomography coronary angiography to detect significant coronary artery disease in patients referred for cardiac valve surgery. J Am Coll Cardiol 2006; 48:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/28\">",
"      Bonow RO, Cheitlin MD, Crawford MH, Douglas PS. Task Force 3: valvular heart disease. J Am Coll Cardiol 2005; 45:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/29\">",
"      Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol 2005; 45:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/30\">",
"      Salem DN, O'Gara PT, Madias C, et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:593S.",
"     </a>",
"    </li>",
"    <li>",
"     Wilson W, Taubert KA, Gewitz M, et al. Prevention of Infective Endocarditis. Guidelines From the American Heart Association. A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007; 115 published online April 19, 2007. www.circ.ahajournals.org/cgi/reprint/CIRCULATIONAHA.106.183095v1 (Accessed on May 04, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/32\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/33\">",
"      Daniel WG, Hood WP Jr, Siart A, et al. Chronic aortic regurgitation: reassessment of the prognostic value of preoperative left ventricular end-systolic dimension and fractional shortening. Circulation 1985; 71:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/34\">",
"      Carabello BA, Usher BW, Hendrix GH, et al. Predictors of outcome for aortic valve replacement in patients with aortic regurgitation and left ventricular dysfunction: a change in the measuring stick. J Am Coll Cardiol 1987; 10:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/35\">",
"      Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Optimizing timing of surgical correction in patients with severe aortic regurgitation: role of symptoms. J Am Coll Cardiol 1997; 30:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/36\">",
"      Carabello BA. Is it ever too late to operate on the patient with valvular heart disease? J Am Coll Cardiol 2004; 44:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/37\">",
"      Bekeredjian R, Grayburn PA. Valvular heart disease: aortic regurgitation. Circulation 2005; 112:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/38\">",
"      Klodas E, Enriquez-Sarano M, Tajik AJ, et al. Surgery for aortic regurgitation in women. Contrasting indications and outcomes compared with men. Circulation 1996; 94:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/39\">",
"      Tornos P, Sambola A, Permanyer-Miralda G, et al. Long-term outcome of surgically treated aortic regurgitation: influence of guideline adherence toward early surgery. J Am Coll Cardiol 2006; 47:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/40\">",
"      Hammermeister K, Sethi GK, Henderson WG, et al. Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial. J Am Coll Cardiol 2000; 36:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/41\">",
"      Scognamiglio R, Negut C, Palisi M, et al. Long-term survival and functional results after aortic valve replacement in asymptomatic patients with chronic severe aortic regurgitation and left ventricular dysfunction. J Am Coll Cardiol 2005; 45:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/42\">",
"      Carroll JD, Gaasch WH, Zile MR, Levine HJ. Serial changes in left ventricular function after correction of chronic aortic regurgitation. Dependence on early changes in preload and subsequent regression of hypertrophy. Am J Cardiol 1983; 51:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/43\">",
"      Bonow RO, Dodd JT, Maron BJ, et al. Long-term serial changes in left ventricular function and reversal of ventricular dilatation after valve replacement for chronic aortic regurgitation. Circulation 1988; 78:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/44\">",
"      Corti R, Binggeli C, Turina M, et al. Predictors of long-term survival after valve replacement for chronic aortic regurgitation; is M-mode echocardiography sufficient? Eur Heart J 2001; 22:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/45\">",
"      Bhudia SK, McCarthy PM, Kumpati GS, et al. Improved outcomes after aortic valve surgery for chronic aortic regurgitation with severe left ventricular dysfunction. J Am Coll Cardiol 2007; 49:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/46\">",
"      McDonald ML, Smedira NG, Blackstone EH, et al. Reduced survival in women after valve surgery for aortic regurgitation: effect of aortic enlargement and late aortic rupture. J Thorac Cardiovasc Surg 2000; 119:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/47\">",
"      le Polain de Waroux JB, Pouleur AC, Goffinet C, et al. Functional anatomy of aortic regurgitation: accuracy, prediction of surgical repairability, and outcome implications of transesophageal echocardiography. Circulation 2007; 116:I264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/48\">",
"      Minakata K, Schaff HV, Zehr KJ, et al. Is repair of aortic valve regurgitation a safe alternative to valve replacement? J Thorac Cardiovasc Surg 2004; 127:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/49\">",
"      Davierwala PM, David TE, Armstrong S, Ivanov J. Aortic valve repair versus replacement in bicuspid aortic valve disease. J Heart Valve Dis 2003; 12:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/50\">",
"      Aicher D, Langer F, Adam O, et al. Cusp repair in aortic valve reconstruction: does the technique affect stability? J Thorac Cardiovasc Surg 2007; 134:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/51\">",
"      Carr JA, Savage EB. Aortic valve repair for aortic insufficiency in adults: a contemporary review and comparison with replacement techniques. Eur J Cardiothorac Surg 2004; 25:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/52\">",
"      Kallenbach K, Karck M, Pak D, et al. Decade of aortic valve sparing reimplantation: are we pushing the limits too far? Circulation 2005; 112:I253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/53\">",
"      Karck M, Kallenbach K, Hagl C, et al. Aortic root surgery in Marfan syndrome: Comparison of aortic valve-sparing reimplantation versus composite grafting. J Thorac Cardiovasc Surg 2004; 127:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/29/25050/abstract/54\">",
"      David TE, Ivanov J, Armstrong S, et al. Aortic valve-sparing operations in patients with aneurysms of the aortic root or ascending aorta. Ann Thorac Surg 2002; 74:S1758.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8160 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25050=[""].join("\n");
var outline_f24_29_25050=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS AND COURSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prognostic indicators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Stages and course",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Identification of severe AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Serial monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Chronic AR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bicuspid valves and aortic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Low-risk group",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      High-risk group",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4600874\">",
"      - Concomitant mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10595111\">",
"      - Exercise stress testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10594952\">",
"      - Role of preoperative coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10595029\">",
"      Noninvasive coronary angiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PHYSICAL ACTIVITY AND EXERCISE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Vasodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other forms of medical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ENDOCARDITIS PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      AORTIC VALVE REPLACEMENT OR REPAIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Aortic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Choice of valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Operative mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Risk stratification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Postoperative monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Long-term outcome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Importance of timing of surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - LVEF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Aortic valve repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Minimally invasive surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      AORTIC ROOT DILATATION AND MARFAN SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Aortic valve-sparing reimplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/8160\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8160|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/48/9997\" title=\"figure 1\">",
"      Survival chronic AR LV size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/51/29489\" title=\"figure 2\">",
"      Classification exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/41/17054\" title=\"figure 3\">",
"      Functional class outcome AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/43/702\" title=\"figure 4\">",
"      AR postoperative outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8160|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?30/9/30867\" title=\"movie 1\">",
"      Parasternal long axis echo aortic valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/28/21954\" title=\"movie 2\">",
"      Parasternal long axis echo close up aortic valve vegetation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?21/47/22260\" title=\"movie 3\">",
"      Aortic valve endocarditis long axis color Doppler echocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?29/38/30306\" title=\"movie 4\">",
"      TEE mitral valve aneurysm from endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/8160|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/37/604\" title=\"table 1\">",
"      Natural history of chronic AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/52/6989\" title=\"table 2\">",
"      ACC AHA diagnosis evaluation AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/8/7308\" title=\"table 3\">",
"      Stages of aortic regurgitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/19/22844\" title=\"table 4\">",
"      Severity of AR in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/34/24107\" title=\"table 5\">",
"      Bicuspid AV dilated asc aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/4/29772\" title=\"table 6\">",
"      Coronary angio valve disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/39/4732\" title=\"table 7\">",
"      Vasodilators in chronic AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 8\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/53/24412\" title=\"table 9\">",
"      ACC AHA AVR in chronic AR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/4/40011\" title=\"table 10\">",
"      AV surgery in chronic AR young",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/61/10204\" title=\"table 11\">",
"      ACC AHA selection aortic valve",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/35/20022?source=related_link\">",
"      Acute aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/32/1543?source=related_link\">",
"      Angiotensin converting enzyme inhibitors and receptor blockers in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/1/6169?source=related_link\">",
"      Clinical manifestations and diagnosis of bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/3/1082?source=related_link\">",
"      Echocardiographic evaluation of the aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/5/7252?source=related_link\">",
"      Estimating the mortality risk of valvular surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/59/28601?source=related_link\">",
"      Evaluation and management of asymptomatic left ventricular systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=related_link\">",
"      Management of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/38/30310?source=related_link\">",
"      Minimally invasive aortic and mitral valve surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/26/20906?source=related_link\">",
"      Noninvasive coronary imaging with cardiac computed tomography and cardiovascular magnetic resonance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/9/38039?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/50/20262?source=related_link\">",
"      Pregnancy and Marfan syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27032?source=related_link\">",
"      Pregnancy in women with a bicuspid aortic valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13898?source=related_link\">",
"      Risk of sudden cardiac death in athletes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11865?source=related_link\">",
"      Surgical valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3015?source=related_link\">",
"      Treatment of Takayasu arteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7078?source=related_link\">",
"      Treatment of bicuspid aortic valve stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14567?source=related_link\">",
"      Vasodilator therapy in severe chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_29_25051="Causes of vertigo";
var content_f24_29_25051=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F66539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F66539&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of vertigo",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Peripheral causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign paroxysmal positional vertigo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vestibular neuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Herpes zoster oticus (Ramsay Hunt syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Meniere disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Labyrinthine concussion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Perilymphatic fistula",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Semicircular canal dehiscence syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cogan's syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recurrent vestibulopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acoustic neuroma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aminoglycoside toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Otitis media",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Central causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Migrainous vertigo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brainstem ischemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebellar infarction and hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chiari malformation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sclerosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Episodic ataxia type 2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25051=[""].join("\n");
var outline_f24_29_25051=null;
var title_f24_29_25052="External otitis microbiology A";
var content_f24_29_25052=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64716&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acute external otitis microbiology",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Organism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\" rowspan=\"1\">",
"        Aerobic bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Pseudomonas",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        S. aureus",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Strep group D &amp; G",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3_start\" colspan=\"1\">",
"        Other gram negative",
"       </td>",
"       <td class=\"sublist_other_start\" colspan=\"1\" rowspan=\"4\">",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        H. influenzae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        Proteus sp",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist3\">",
"        E. coli",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Anaerobic bacteria",
"       </td>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Bacteroides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Clostridii",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Streptococci",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Commensals",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        46",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        S. epidermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Diptheroids",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\" rowspan=\"1\">",
"        Fungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Candida albicans",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Aspergillus",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        No growth",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Number of organisms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Single organism",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mixed",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Percent of total patients with growth of this organism (n = 100).",
"    </div>",
"    <div class=\"reference\">",
"     Data from Russell, JD, Donnelly, M, McShane, DP, et al, J Laryngol Otol 1993; 107:898.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25052=[""].join("\n");
var outline_f24_29_25052=null;
var title_f24_29_25053="Protein intake and stones";
var content_f24_29_25053=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F56597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F56597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Protein load increases urine stone-forming tendency",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 254px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The institution of a high protein diet (2 g/kg per day) in normal men adversely effects the metabolic parameters determining the risk of calcium stone formation. There is an increase in the urinary excretion of calcium and uric acid and a reduction in that of citrate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Kok, DJ, Iestra, JA, Doorenbos, CJ, Papapoulos, SE, J Clin Endocrinol Metab 1990; 71:861.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25053=[""].join("\n");
var outline_f24_29_25053=null;
var title_f24_29_25054="Efficacy of EP guided therapy";
var content_f24_29_25054=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Efficacy of EP-guided antiarrhythmic therapy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 470px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Outcome among patients with life-threatening ventricular arrhythmia who underwent electrophysiologic-guided drug therapy. Sudden death and cardiac death were significantly lower among the patients in whom an effective antiarrhythmic drug was identified (responders, n = 103) when compared to those in whom no effective drug could be identified (nonresponders, n = 102).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Swerdlow CD, Winkle RA, Mason JW. N Engl J Med 1983; 308:1426.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25054=[""].join("\n");
var outline_f24_29_25054=null;
var title_f24_29_25055="ACP algorithm management high risk patients";
var content_f24_29_25055=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    American College of Physicians algorithm for the management of patients at high risk for perioperative cardiac events (myocardial infarction and death)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 450px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Boxed phrases indicate recommended actions.",
"    <br>",
"     The green bolded words beside the boxes indicate the level of evidence supporting the recommendation. If no green bolded word is present, no evidence exists for or against use.",
"     <div class=\"footnotes\">",
"      AHA: American Heart Association.",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from Palda, et al. Ann Intern Med 1997; 127:309. Copyright &copy; 1997 American College of Physicians.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_29_25055=[""].join("\n");
var outline_f24_29_25055=null;
